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A B S T R A C T
Background
Crohn’s disease (CD) is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. 5-Aminosalicylates (5-
ASAs) are locally acting, anti-inflammatory compounds that reduce inflammation of the colonic mucosa with release profiles that vary
among various commercially available formulations. This updated Cochrane review summarizes current evidence on the use of 5-ASA
formulations for maintenance of surgically-induced remission in CD.
Objectives
To assess the efficacy and safety of 5-ASA agents for the maintenance of surgically-induced remission in CD.
Search methods
We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register from inception to 16 July 2018. We
also searched references, conference abstracts, and trials registers.
Selection criteria
Randomised controlled trials (RCTs) that included participants with CD in remission following surgery and compared 5-ASAs to no
treatment, placebo or any other active intervention with duration of at least three months were considered for inclusion.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. The primary outcome was clinical relapse. Secondary outcomes
included endoscopic recurrence, radiologic and surgical relapse, adverse events, serious adverse events and withdrawal due to adverse
events.
Main results
Fourteen RCTs (1867 participants) were included in the review. Participants (15 to 70 years) were recruited from gastroenterology
hospitals and medical clinics in Europe and North America and followed up between 3 and 72 months. The risk of bias was assessed
as ’low’ in one study, ’unclear’ in seven and as ’high’ in six.
At 12 months, 36% (20/55) of participants in the 5-ASA group experienced clinical relapse compared to 51% (28/55) in the no
treatment control group (RR 0.71, 95% CI 0.46 to 1.10; low certainty evidence). Moderate certainty evidence suggests that 5-ASAs
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are more effective for preventing clinical relapse than placebo. During a follow-up period of 12 to 72 months, 36% (131/361) of 5-
ASA participants relapsed compared to 43% (160/369) of placebo participants (RR 0.83, 95% CI 0.72 to 0.96; I² = 0%; moderate
certainty evidence). At 12 months, 17% (17/101) of the 4 g/day mesalamine group relapsed compared to 26% (27/105) of the 2.4 g/
day group (RR 0.65, 95% CI 0.38 to 1.13; moderate certainty evidence). There was no evidence of a difference in clinical relapse rates
when 5-ASA compounds were compared to purine antimetabolites. At 24 months, 61% (103/170) of mesalamine participants relapsed
compared to 67% (119/177) of azathioprine participants (RR 0.90, 95% CI 0.76 to 1.07; I² = 28%; low certainty evidence). During
24 months, 50% (9/18) of 5-ASA participants had clinical relapse compared to 13% (2/16) of adalimumab participants (RR 4.0, 95%
CI 1.01 to 15.84; low certainty evidence). The effects of sulphasalazine compared to placebo on clinical relapse rate is uncertain. After
18 to 36 months, 66% (95/143) of participants treated with sulphasalazine relapsed compared to 71% (110/155) in the placebo group
(RR 0.88, 95% CI 0.56 to 1.38; I² = 38%; low certainty evidence).
The effect of 5-ASA drugs on safety was uncertain. During 24 months follow-up, 4% (2/55) of 5-ASA participants experienced adverse
events compared to none (0/55) in the no treatment control group (RR 5.00, 95% CI 0.25 to 101.81; very low certainty evidence).
An equal proportion of 5-ASA participants (10%; 23/241) and placebo (9%; 20/225) groups experienced an adverse event during a
follow-up of 3 to 72 months (RR 1.07, 95% CI 0.60 to 1.91; I² = 0%; low certainty evidence). Adverse event rates were similar in
the 5-ASA and purine analogues groups. However, serious adverse events and withdrawals due to adverse events were more common
in participants who received purine analogues than 5-ASA. At 52 weeks to 24 months, 52% (107/207) of 5-ASA participants had an
adverse event compared to 47% (102/218) of purine analogue participants (RR 1.11, 95% CI 0.97 to 1.27, I² = 0%; low certainty
evidence). Four per cent (6/152) of 5-ASA participants had a serious adverse event compared to 17% (27/159) of purine analogue
participants (RR 0.30, 95% CI 0.11 to 0.80; very low certainty evidence). Eight per cent (17/207) of 5-ASA participants withdrew
due to an adverse event compared to 19% (42/218) of purine analogue participants (RR 0.48, 95% CI 0.28 to 0.83; low certainty
evidence). Adverse event rates were similar in high and low dose mesalamine participants. After 12 months, 2% (2/101) of 4 g/day
mesalamine participants had an adverse event compared to 2% (2/105) of 2.4 g/day participants (RR 1.04, 95% CI 0.15 to 7.24;
low certainty evidence). The proportion of participants who experienced adverse events over a 24 month follow-up in the mesalamine
group was 78% (14/18) compared to 69% (11/16) of adalimumab participants (RR 1.13, 95% CI 0.75 to 1.71; very low certainty
evidence). None (0/32) of the sulphasalazine participants had an adverse event at 18 months follow-up compared to 3% (1/34) of
the placebo group (RR 0.35, 95% CI 0.01 to 8.38; very low certainty evidence). Commonly reported adverse events in the included
studies were diarrhoea, nausea, increased liver function tests, pancreatitis, and abdominal pain.
Authors’ conclusions
5-ASA preparations are superior to placebo for the maintenance of surgically-induced clinical remission in patients with CD (moderate
certainty). The number needed to treat to prevent one relapse was 13 patients. The evidence for endoscopic remission is uncertain.
The sulphasalazine class of 5-ASA agents failed to demonstrate superiority against placebo, 5-ASAs failed to demonstrate superiority
compared to no treatment (very low and low certainty). The efficacy of two different doses of the same 5-ASA and the efficacy of
5-ASA compared to purine antimetabolites (azathioprine or 6-mercaptopurine) in maintaining surgically-induced remission of CD
remains unclear. However, purine analogues lead to more serious adverse events and discontinuation due to adverse events. There is a
low certainty that 5-ASA is inferior for maintaining surgically-induced remission of CD compared to biologics (anti TNF- ). 5-ASA
formulations appear to be safe with no difference in the occurrence of adverse events or withdrawal when compared with placebo, no
treatment or biologics.
P L A I N L A N G U A G E S U M M A R Y
Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
What is the aim of this review?
The aim of this review was to understand the effectiveness and safety of 5-ASA drugs for maintaining remission following surgery in
people with Crohn disease. This review is an update of a previously published Cochrane review.
What is Crohn’s disease?
Crohn’s is a chronic disease of the gut. Crohn’s changes from periods when sufferers have symptoms (relapse) to periods when the
symptoms disappear (remission). Symptoms include abdominal pain, diarrhoea and weight loss. People with Crohn’s disease may
undergo surgery to remove diseased parts of their gut. However, their symptoms may return after a short time. Different drugs can
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be given to maintain remission, however, there are concerns about possible side effects. 5-ASA drugs reduce inflammation (pain and
swelling) in the gut. We researched whether 5-ASA can maintain remission in people with Crohn’s after the diseased part of their gut
has been removed.
How up-to-date is this review?
The review authors searched for studies that had been published up to 16 July 2018.
What are the main results of the review?
We found 14 studies (1867 participants). One study was judged to be of high quality, six studies were of low quality and seven were
judged to be unclear as authors reported insufficient information to allow a judgement. People who took 5-ASA had fewer relapses than
people who had no maintenance treatment. At 12 months, 36% (20/55) of participants in the 5-ASA group relapsed compared to 51%
(28/55) in the no treatment control group (1 study, low certainty evidence). Moderate quality evidence from five studies showed that
5-ASA drugs are superior to placebo (e.g. a sugar pill) for maintaining surgically-induced remission of Crohn’s disease. During a follow-
up period of 12 to 72 months, 36% (131/361) of 5-ASA participants relapsed compared to 43% (160/369) of placebo participants.
The analysis of four studies that compared 5-ASA medications to purine antimetabolites (i.e. azathioprine or 6-mercaptopurine - both
immunosuppressive drugs) found no difference in the proportion of participants that remained in remission, although the overall
quality of evidence was low. At 24 months, 61% (103/170) of 5-ASA participants relapsed compared to 67% (119/177) of purine
antimetabolite participants. People who took high dose 5-ASA had fewer relapses than those who took lower dose 5-ASA. At 12
months, 17% (17/101) of the 4 g/day 5-ASA group relapsed compared to 26% (27/105) of the 2.4 g/day group (1 study, moderate
certainty evidence). The analysis of the single small study that compared 5-ASA and adalimumab (a biologic drug) showed that 5-
ASA was inferior to adalimumab for maintaining surgically-induced remission of Crohn’s disease. At 24 months, 50% (9/18) of 5-
ASA participants relapsed compared to 13% (2/16) in the adalimumab group (very low certainty evidence). The analysis of two studies
that compared sulphasalazine to placebo found no difference in relapse rates. After 18 to 36 months, 66% (95/143) of sulphasalazine
participants relapsed compared to 71% (110/155) of placebo participants (low certainty evidence). There was no difference in rates of
side effects, serious side effects and withdrawal due to side effects when 5-ASA was compared to placebo. 5-ASA was safer than purine
analogues resulting in less serious side effects and discontinuation of treatment due to side effects. Commonly reported side effects
included diarrhoea, nausea, increased liver function tests, pancreatitis and abdominal pain.
Conclusions
5-ASA drugs are superior to placebo for maintaining surgically-induced remission of Crohn’s disease (moderate certainty evidence).
Sulphasalazine failed to demonstrate superiority against placebo (very low certainty evidence), and similarly 5-ASAs failed to demonstrate
superiority to no treatment (low certainty evidence). The effectiveness of two different doses of the same 5-ASA and the effectiveness of
5-ASA compared to purine antimetabolites (azathioprine or 6-mercaptopurine) for maintaining surgically-induced remission of Crohn’s
disease remains unclear. However, purine analogues lead to more serious side effects and discontinuation due to side effects than 5-
ASA. There is a low certainty that 5-ASA is inferior to adalimumab for maintaining surgically-induced remission of CD. There was
no evidence of a difference in the occurrence of side effects or withdrawal due to side effects with 5-ASA formulations when compared
with placebo, no treatment or biologics.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
5-ASA compared to no treatment for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: people with surgically-induced remission in Crohn’s disease
Setting: outpat ient
Intervention: 5-ASA (2.4 g/ day)
Comparison: no Treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no treatment Risk with 5-ASA
Clinical relapse
Follow-up: 12 months
509 per 1,000 361 per 1,000
(234 to 560)
RR 0.71
(0.46 to 1.10)
110
(1 Study)
⊕⊕©©
LOW 12
Patients in whom CDAI
was > 150, and who pre-
sented 100 points over
their previous value,
were considered to be
relapsed (Caprilli 1994)
Endoscopic recurrence Outcome not reported Not reported
Radiologic relapse Outcome not reported Not reported
Adverse events
Follow-up: 12 months
0 per 1,000 0 per 1,000
(0 to 0)
RR 5.00
(0.25 to 101.81)
110
(1 Study)
⊕©©©
VERY LOW 13
We were unable to
calculate absolute ef -
fects. Adverse events
occurred in 4% (2/ 55)
of part icipants in the
5-ASA group compared
to 0% (3/ 55) in the no
treatment control group
Re-
ported adverse events
included skin rash, epi-
gastric pain, vomit ing
and nausea4
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Serious adverse events Outcome not reported Not reported
Withdrawal due to ad-
verse events
Follow-up: 12 months
0 per 1,000 0 per 1,000
(0 to 0)
RR 5.00
(0.25 to 101.81)
110
( 1 study)
⊕©©©
VERY LOW 13
We were unable to
calculate absolute ef -
fects. Adverse events
occurred in 4% (2/ 55)
of part icipants in the
5-ASA group compared
to 0% (3/ 55) in the no
treatment control group
Withdrawals due to ad-
verse events included
skin rash, epigastric
pain, vomit ing and nau-
sea
Health related quality
of life
Outcome not reported Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high risk of performance bias and unclear risk of select ion of bias
2 Downgraded one level due to serious imprecision (48 events)
3 Downgraded two levels due to very serious imprecision (2 events)
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B A C K G R O U N D
Description of the condition
Crohn’s disease is a chronic inflammatory disorder that can involve
any part of the gastrointestinal tract. There is no cure for the
disease, somanagement strategies are instead focused on induction
and maintenance of remission, as well as supporting the many
other symptoms that impact patients affected by the condition.
Approximately 75% of patients with Crohn’s disease will even-
tually undergo surgical resection and this can induce remission
(Bernell 2000). Recent studies suggest a rate of 3.8 operations
per 100 person years (Ma 2017). However, endoscopic recurrence
of disease has been reported to be as high as 73% at one year
post surgery (Rutgeerts 1990), and clinical relapse rates have been
reported to range from 20% to 86% at five years post surgery
Rutgeerts 2002; Gklavas 2017).
Given these high relapse rates, there have been many studies to
identify potential methods of prolonging postoperative remission,
but there is no standard therapy for the prevention of postoperative
recurrence in Crohn’s disease (NICE 2012). A number of agents
have been studied, but considerable uncertainty remains as to the
efficacy of such treatments. 5-aminosalicylates are currently not
recommended for maintenance of surgically-induced endoscopic
remission (Nguyen 2017; NICE 2019).
Description of the intervention
5-aminosalicylates are a group of compounds that have long been
used in inflammatory bowel disease. The first 5-aminosalicylate
agent used in clinical practice was sulphasalazine. Sulphasalazine is
composed of sulphapyridine linked by an azo bond to 5-aminos-
alicylic acid (5-ASA). Sulphasalazine was first used in the 1940s as
a treatment for arthritis (Svartz 1942). Improvement in gastroin-
testinal symptoms was noted in patients who had concurrent ul-
cerative colitis leading to further use of this agent in inflammatory
bowel disease.
When the oral dose of sulphasalazine reaches the colon, an azo-
reductase synthesised by colonic bacteria splits the azo-bond yield-
ing 5-ASA and sulphapyridine. Literally all the sulphapyridine
compound is being absorbed from the colon, while most of 5-
ASA remains in the colon and is excreted in the faeces. The role
of sulphapyridine as a carrier molecule is to deliver 5-ASA, the
active therapeutic moiety of sulphasalazine, to the colon (Azad
Khan 1977; Klotz 1980; van Hees 1980). However, the most se-
vere adverse effects of sulphasalazine are caused by sulphapyri-
dine (Schroder 1972). Sulphapyridine undergoes acetylation in
the liver with subsequent excretion in the urine. Slow acetylator
show more of the adverse effects of this component secondary to
accumulation of sulphapyridine in the blood prior to excretion in
the kidneys (Das 1973). A number of investigations of the use of
5-ASA as a single agent for the treatment of inflammatory bowel
disease have recognised that 5-ASA is indeed the active ingredient
of sulphasalazine and that sulphapyridine is responsible formost of
the side effects. 5-ASA in its unprotected form is, however, readily
absorbed in the proximal small intestine (Myers 1987), and does
not reach the distal bowel in therapeutic concentrations. Several 5-
ASA formulations have been designed in order to inhibit proximal
absorption and enable delivery to distal sites of inflammation. The
protection of 5-ASA compound can be achieved either by linking
it to itself or to another carrier or by using slow release preparations
of 5-ASA. Different 5-ASA preparations may allow delivery of 5-
ASA to different locations in the gastrointestinal tract.
How the intervention might work
5-aminosalicylic acid agents are locally acting, anti-inflammatory
compounds that reduce inflammation of the colonic mucosa with
release profiles that vary among various commercially available
formulations (Abinusawa 2015). However, in order to express
an antiinflammatory effect seen through a negative regulation
of cyclooxygenase and lipoxygenase pathways and prevention of
prostaglandin and leukotrienes formation (Ligumsky 1981), and
increased peroxisome proliferator-activated receptors expression
(Rousseaux 2005), 5-ASA agentsmust be able to directly target the
terminal ileum and colon. The commonly used oral 5-ASA formu-
lations include azo compounds, mesalazine delayed-release agents
and mesalazine slow-release formulations. For azo compounds, a
carrier molecule is linked to 5-ASA by an azo bond using the same
principle as sulphasalazine. Olsalazine consists of two molecules
of 5-ASA joined together, whilst balsalazide is a prodrug in which
a 5-ASA molecule is linked to 4-aminobenzoyl-B-alanine, an in-
ert and biologically inactive carrier molecule. Like sulphasalazine,
the azo bond of these drugs is split in the colon by bacterial azo
reductases, releasing 5-ASA to exert local therapeutic activity. The
5-ASA compound of immediate-release oral mesalamine formula-
tions is quickly absorbed in the upper gastrointestinal tract result-
ing in a negligible clinical effect (Rasmussen 1982; Shafil 1982).
Therefore, in order to provide stable delivery of the active 5-ASA
compound to the colon, controlled-release and pH dependent
oral mesalamine agents have been developed (Rasmussen 1982).
Mesalazine delayed-release agents (Eudragit-coated) are coated
with a resin designed to dissolve at a certain pH which gradually
increases from the stomach (approximate pH = 2) via the small
intestine (pH = 6) to the colon (pH = 7 to 8) (Nugent 2001).
Asacol is coated with Eudragit S which dissolves above pH 7.0 to
release 5-ASA in the terminal ileum and colon. Eudragit-L coated
mesalazine (Salofalk) dissolves above pH 6.0 to release 5-ASA in
the terminal ileum and colon. Mesalazine slow-release formula-
tions include drugs such as Pentasa. Pentasa contains microgran-
ules of 5-ASA that are individually coated with ethylcellulose. The
microgranules are dispersed in the gut providing a slow,steady re-
lease of 5-ASA along the length of the intestine from the upper
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small bowel to the colon. These 5-ASA preparations were intended
to avoid the adverse side effects of sulphasalazine whilst maintain-
ing its therapeutic benefits.
Several randomised controlled trials have been published, com-
paring various 5-ASA agents to placebo, with contradicting results
(De Franchis 1997; Gendre 1993; Mahmud 2001). Three previ-
ous meta-analyses have suggested that 5-ASA may be beneficial
for the maintenance of medically-induced remission in Crohn’s
disease (Camma 1997; Messori 1994; Steinhart 1994), but in one
report the only bibliographic database searched was MEDLINE
(Camma 1997), and another meta-analysis did not report how
the quality of included studies was assessed (Messori 1994). A
Cochrane review on the use of 5-ASA agents for the maintenance
of medically-induced remission in Crohn’s disease completed in
2005 concluded that there was no evidence to suggest that 5-ASA
preparations were superior to placebo for themaintenance of med-
ically-induced remission in Crohn’s disease (Akobeng 2005). This
review was recently updated and again there was no evidence to
suggest that 5-ASA was efficacious in this setting, although these
agents had a good safety profile (Akobeng 2016).
Why it is important to do this review
5-ASA agents have been studied extensively in the post-operative
setting, and a previous meta-analysis published in 1997 suggested
that 5-ASA agents may be beneficial for the prevention of post-
operative recurrence in Crohn’s disease (Camma 1997). However,
at least one subsequent multicentre randomised controlled trial
failed to show an overall benefit compared with placebo (Lochs
2000). A previous review by this team in 2011 found evidence
that 5-ASA may be efficacious and safe in the post-surgical setting
(Gordon 2011). However, an updated systematic review using the
Cochrane Collaboration format is indicated to summarise the cur-
rent evidence on the use of 5-ASA agents for the maintenance of
surgically-induced remission in Crohn’s disease.
O B J E C T I V E S
The primary objective was to evaluate the efficacy of 5-ASA agents
for the maintenance of surgically-induced remission in Crohn’s
disease. The secondary objective was to determine the frequency
of adverse events associated with the use of 5-ASA agents for the
maintenance of remission in Crohn’s disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials which compared sulphasalazine and
5-ASA agents to either placebo or another intervention, with treat-
ment durations of at least three months were considered for inclu-
sion.
Types of participants
Participants of any age and sex with a diagnosis of Crohn’s dis-
ease confirmed by any established method who were in remission
following surgery, defined by a recognized Crohn’s disease activity
index or endoscopy, or patients who have undergone a curative
surgical resection, as defined by the authors of the primary studies
were considered for inclusion. Trials conducted in any setting (e.g.
single-centre or multicentre) with no language restrictions were
considered for inclusion.
Types of interventions
The controlled interventions of interest included any randomised
controlled trial which compared any oral 5-ASA agents to a no
treatment control, placeboor another active intervention formain-
tenance of surgically-induced remission in Crohn’s disease. For
this review, studies employing sulphasalazine preparations have
been analysed separately, given that these agents have a unique
biochemical structure to other 5-ASA preparations. For the main
analysis, all other 5-ASA preparations were considered together
and for the purposes of the nomenclature of this review, were
termed ’5-ASA’. Studies that compared sulphasalazine or 5-ASA
agents to an intervention that focuses on enteral nutrition, oral
nutrient supplementation, herbal medicines, medical foods, pro-
biotics or parental nutrition, as well as dose optimisation studies
were excluded.
Types of outcome measures
Primary outcomes
The primary outcome measure was clinical relapse as defined by
the primary studies. We accepted the authors’ definitions of what
constitutes a clinical relapse.
Secondary outcomes
Secondary outcome measures included:
1) Endoscopic recurrence, as defined by the original studies;
2) Radiologic relapse, as defined by the original studies;
3) Adverse events;
4) Serious adverse events;
5) Withdrawal due to adverse events; and
6) Health related quality of life (HRQoL).
We reported outcome measures at the last time point available
(assumed tobe at the endof follow-up if not specified) and the time
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point specified in the methods as being of primary interest (if this
was different from the latest time point available). However, we
also indicated when studies report outcomes at other time points.
Search methods for identification of studies
Electronic searching
We searched the following databases from inception to 16 July
2018:
1. MEDLINE (National Library of Medicine, Bethesda, USA);
2. Embase (Elsevier Science, New York, USA);
3. CENTRAL; and
4. Cochrane IBD Group Specialized Register.
No restrictions were placed on publication dates or language. Note
that the searches were designed to include RCTs conducted in
adults and children, but exclude trials that compare 5-ASA to
oral nutrition supplements (enteral nutrition drinks, tube feeds),
medical foods, probiotics, parenteral nutrition or a combination
of these modalities. The search strategies are reported in Appendix
1.
Searching other resources
Reference searching
We searched reference lists from included articles and any existing
relevant reviews.
Abstracts of major gastroenterology meetings
A manual search of abstracts submitted to major gastroenterology
meetings (2015 to 2018) was performed for the following journals
to identify more trials that may have not been published in full at
the time of the review:
1. Gastroenterology (American Gastroenterological Association);
2. Gut (British Society of Gastroenterology);
3. American Journal of Gastroenterology (American College of
Gastroenterology);
4. Canadian Journal of Gastroenterology (Canadian Association
of Gastroenterology);
5. Journal of Pediatric Gastroenterology and Nutrition (European
Society of Paediatric Gastroenterology, Hepatology and Nutri-
tion); and
6. Journal of Pediatric Gastroenterology and Nutrition (North
American Society of Paediatric Gastroenterology, Hepatology and
Nutrition).
When a relevant abstract was identified, details of the full study
methodology and results were requested from the authors in order
to allow a thorough assessment of the quality of identified studies.
Abstracts for which this information could not be obtained were
excluded.
Trials Registers
We searched clinicaltrials.gov and the WHO International Clini-
cal Trials Registry Platform (ICTRP) for ongoing studies.
Data collection and analysis
Selection of studies
Two authors (MG and TGH) independently reviewed each ar-
ticle at each stage of selection including title screening, abstract
screening and full-text review. Included and excluded studies were
recorded.
Step 1. Title screening using the above search strategy, papers (or
abstracts) that appeared to have even a minor possibility of inclu-
sion were selected by two authors (MG and TGH). Adjudication
did not occur at the title screening stage and studies that were
ambiguous were included by default.
Step 2. Abstract screening: involved selection of articles that report
studies with a reasonable possibility of inclusion. Differences in
assessment for inclusion were resolved by discussion between the
two independent investigators (MG and TGH). Adjudication did
not occur at the abstract screening state.
Step 3. Full-text review involved selection of articles based on care-
ful examination of the full report. Differences in assessment for in-
clusion were resolved by discussion between the two independent
investigators. Adjudication was performed as needed by a third
author (ZIE).
Data extraction and management
Two authors (ZEI and TGH) independently extracted and
recorded the data using a data extraction form developed to ex-
tract information on relevant features and results of the included
studies. Extracted data included the following items:
• Study design (type of RCT, setting, number of
interventions, year, author’s contact details);
• Population characteristics: age, sex, disease distribution,
disease duration, site of disease, medication, type and time since
operation, total number of patients originally assigned to each
treatment group;
• Intervention: type and dose of agent;
• Control: no active treatment, placebo, other drugs;
• Concurrent medications; and
• Outcomes: time of assessment, length of follow-up, type of
Crohn’s disease activity index used, definitions of remission and
relapse, site of surgery, relapse rates, adverse events.
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Assessment of risk of bias in included studies
Two authors (ZEI and TGH) independently assessed the risk of
bias using the Cochrane risk of bias tool (Higgins 2011). Adju-
dication was performed as needed by a third author (MG). Each
domain was assessed as having a low, moderate, high, or unclear
risk of bias. Domaines assessed include:
• Sequence generation (i.e. was the allocation sequence
adequately generated?);
• Allocation sequence concealment (i.e. was allocation
adequately concealed?);
• Blinding of participants and personnel and outcome
assessors (i.e. was knowledge of the allocated intervention
adequately prevented during the study?);
• Incomplete outcome data (i.e. were incomplete outcome
data adequately addressed?);
• Selective outcome reporting (i.e. are reports of the study
free of suggestion of selective outcome reporting?); and
• Other potential sources of bias (i.e. was the study apparently
free of other problems that could put it at a high risk of bias?).
Each domain followed standard definitions used for Cochrane sys-
tematic reviews (Higgins 2011). Based on the aggregate assessment
of these items, study quality was rated as good (low risk of bias),
fair, or poor (high or unclear risk of bias). Study authors were con-
tacted for further information when insufficient information was
provided to determine the risk of bias.
Summary of findings tables
The overall strength of evidence supporting the primary outcome
and selected secondary outcomes was assessed using the GRADE
(Grades of Recommendation, Assessment, Development, and
Evaluation) criteria (Guyatt 2008; Schünemann 2011). For the
’Summary of findings’ tables, we included the following outcomes:
clinical relapse, endoscopic recurrence, radiologic relapse, adverse
events, serious adverse events, study withdrawal due to adverse
events and health-related quality of life. Though evidence from
RCTs starts as high quality, the quality of the evidence can be
downgraded due to: risk of bias, indirect evidence, inconsistency
(unexplained heterogeneity), imprecision and publication bias.
Taking all of these factors into account, we rated the overall quality
of evidence as follows:
• High - we are very confident that the true effect lies close to
that of the estimate of the effect;
• Moderate - we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different;
• Low - our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect; or
• Very low. We have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
Measures of treatment effect
For binary outcomes, we calculated the risk ratio (RR) estimates
and associated two-sided 95% confidence intervals (CI). For nom-
inal or ordinal outcomes, we planned to calculate the RR with
corresponding 95% for each category relative to a reference cate-
gory. For continuous outcomes, we calculated the mean difference
(MD) and corresponding 95% CI.
Unit of analysis issues
The unit of analysis was the individual participant. We planned to
include cross-over trials if data were available from the first phase
of the study (i.e. before cross-over occurred). For outcomes where
events recur (e.g. clinical relapses, adverse events), we calculated
the proportion of patients who experienced at least one event. In-
dividual events were not counted separately. The studies were oth-
erwise not anticipated to have repeated observations of outcomes
or multiple treatment events.
Dealing with missing data
Information on how each trial handledmissing data was recorded.
When a study appeared to collect and not report on all primary
outcomes of interest, the original investigators were contacted to
request missing data. If the original investigators did not provide
the data, this would be noted in the systematic review. For stud-
ies with missing dichotomous data, a separate intention-to-treat
analysis was performed where participants with missing data were
assumed to have been treatment failures. For the main analysis,
the total number of patients was used as a denominator. It was
assumed that participants who dropped out of the study, and on
whom there was no post withdrawal information, had relapsed
during the study period. For missing continuous data, we used an
available case analysis.
Assessment of heterogeneity
Heterogeneity and inconsistency was assessed to ensure the valid-
ity of the analysis. Initially heterogeneity was assessed through vi-
sual inspection of forest plots and the calculation of the Chi² and
I² statistics (Boreinstein 2009). For studies that had qualitative
homogeneity, statistical heterogeneity was assessed using the Chi²
test (P value < 0.10 was considered statistically significant hetero-
geneity). The degree of heterogeneity across studies was estimated
using the I² statistic. An I² of 25% or less was considered low
heterogeneity, 26 to 50% was considered moderate heterogene-
ity, and 50% and greater was considered substantial heterogene-
ity. Possible explanations for heterogeneity were examined where
sufficient data were available, including factors such as participant
characteristics (e.g. age, sex), disease condition severity, treatment
type and dose, and healthcare system/country.Where appropriate,
these factors were investigated further through sub-group analyses
and meta-regression (Boreinstein 2009). Sensitivity analyses were
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used to explore possible causes of methodological heterogeneity,
where sufficient data were available (Sutton 2000). This included
assessing the effects of studies that may be affected by factors such
as risk of bias associated with allocation concealment, high loss to
follow-up or lack of blinding in assessment of outcomes.
Assessment of reporting biases
If there were an appropriate number of studies in a pooled analysis
(i.e. > 10 studies), we planed to investigate potential publication
bias using funnel plots (trial effects versus trial size). However, the
number of studies in each comparison group was smaller than 10.
Data synthesis
The Cochrane Collaboration review manager (RevMan) software
(version 5.3.5) was used for data analyses. Data were analysed
according to the intention-to-treat principle. Patients with final
missing outcomes were assumed to have relapsed.
Analyses were grouped by type of intervention treatment (e.g. 5-
ASA versus purine analogues, 5-ASA versus placebo). Studies were
synthesised through a narrative review with tabulation of results
of included studies. Where possible, treatment effects for all com-
parisons and outcomes were synthesized through meta-analyses,
with the approach taken dependant on the outcome assessed and
the data available (Boreinstein 2009). Although the primary out-
come assessed focused on the dichotomous outcomes of clinical
relapse and endoscopic recurrence, secondary outcomes involved
other data types.
Subgroup analysis and investigation of heterogeneity
We planned to assess the impact of potential effect modifiers such
as age of patients (paediatric versus adult studies) and length of fol-
low-up (12 months or less versus greater than 12 months). How-
ever, there were insufficient data for these analyses.
Sensitivity analysis
Methodological heterogeneity was to be examined through sensi-
tivity analysis, including components of risk of bias and dose of
5-ASA, however, this was not possible due to insufficient data.
R E S U L T S
Description of studies
Results of the search
The results of the updated search conducted on 16 July 2018
are reported in the PRISMA flow diagram (See Figure 1). We
identified 713 records of which 546 citations remained after du-
plicates were removed. Following title and abstract screening,
33 potentially relevant reports were identified and subjected to
further scrutiny. Fourteen RCTs (1867 participants) reported
in 23 articles satisfied the inclusion criteria and were included
in this review (Ardizzone 2004; Brignola 1995; Caprilli 1994;
Caprilli 2003; Ewe 1989; Florent 1996; Hanauer 2004; Herfarth
2006; Lochs 2000; McLeod 1995; Reinisch 2010; Savarino 2013;
Sutherland 1997; Wenckert 1978). One study was awaiting clas-
sification (NCT00976690). The rest of the studies were excluded.
Detailed information about these studies are presented in the
Characteristics of included studies, Characteristics of excluded
studies, and additional Table 1 and Table 2, and are summarised
below.
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Figure 1. Study flow diagram
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Included studies
Study design and setting
The 14 RCTs (23 reports) included in this review were single
or multi-centre studies with a duration ranging from 12 weeks
(Florent 1996) to a maximum of 72 months (McLeod 1995). The
included studies were published between 1978 and 2017. There
were two single-centre studies, both conducted in Italy (Ardizzone
2004; Savarino 2013). The multi-centre studies were conducted
in Germany (Ewe 1989; Herfarth 2006), Canada (McLeod 1995;
Sutherland 1997), and Italy (Caprilli 1994; Caprilli 2003), or
as a multinational collaboration of several countries across Eu-
rope (Lochs 2000; Reinisch 2010, Wenckert 1978) and Europe
and the USA (Hanauer 2004). Regarding the trial setting, studies
were conducted either in gastroenterology hospitals and medical
clinics/centres (Ewe 1989; Florent 1996; Lochs 2000; Reinisch
2010; Sutherland 1997; Wenckert 1978, or as a collaboration of
university clinics and hospitals and medical centres (Ardizzone
2004; Brignola 1995;Caprilli 1994;Caprilli 2003;Hanauer 2004;
McLeod 1995; Savarino 2013). Herfarth 2006 did not report the
trial setting.
Participants
The total number of randomised participants included in all 14
trials studies was 1867, with sample sizes ranging between 51
(Savarino 2013) and 324 (Lochs 2000). The participants of the
included studies ranged in age from 15 to 70 years.
The age of participants was reported in most studies and ranged
between an average of 33.6 (Lochs 2000) to 38.4 years (Ardizzone
2004) in 11 trials, while two trials reported age as median (Ewe
1989; Wenckert 1978). Herfarth 2006 did not report on partici-
pant age. All studies appear to have been be conducted on adult
population of both genders, except Wenckert 1978 that included
male and female patients aged > 15 years. None of the studies was
conducted in paediatric patients only.
Maintenance therapy was started less than three months postop-
eratively in all but two studies. One study randomised patients
between 6 to 24 months after surgery (Reinisch 2010), while the
time from, surgery until the start of the intervention remained
unclear in Sutherland 1997.
Interventions were conducted postsurgically in patients with qui-
escent Crohn’s disease established by generally accepted endo-
scopic, histological or radiological criteria, except in Wenckert
1978 where diagnosis of clinical remission and relapse was not
based on index calculation, but on information collected from
special control charts including the presence or absence of symp-
toms such as fever, diarrhoea, rectal bleeding, abdominal pain, ex-
tra-intestinal manifestations, palpable abdominal masses, fistulae,
abscesses and loss of working days. It is important to note that
Reinisch 2010 included participants with subsequent postopera-
tive clinical remission (Crohn’s disease activity indexCDAI < 200),
but with signs of moderate to severe endoscopic recurrence.
The use of concurrent treatment was specifically reported in all but
three studies (Brignola 1995; Ewe 1989; McLeod 1995). In most
of the studies previous treatment with aminosalicylates, metron-
idazole and any other Crohn’s disease specific treatment had to
be discontinued before surgery, while concomitant treatment for
Crohn’s disease during the trial was prohibited. However, corti-
costeroids were allowed to be tapered by standardized stepwise
dose reductions in Ardizzone 2004, Hanauer 2004, and Lochs
2000. Symptomatic treatment with antacids, antidiarrhoeal or
spasmolytic medication on demand was permitted in three stud-
ies (Ardizzone 2004; Caprilli 2003; Lochs 2000), but had to be
scrupulously recorded. Continous use of nonsteroidal anti-inflam-
matory drugs was prohibited and only occasional use of paraceta-
mol and tramadol was allowed in Savarino 2013.
Interventions
Twelve of the included studies were parallel two arm trials with
the exception of Hanauer 2004 and Savarino 2013, both of
which included three intervention arms. The studies compared
the efficacy of sulphasalazine and other oral 5-aminosalicylic acid
treatments to no treatment, placebo or another active treatment.
Given its unique biochemical structure, interventions utilising sul-
phasalazine were analysed separately from the rest of the oral 5-
ASA preparations. Detailed information on study interventions
are reported in additional Table 1 and Table 2 and are summarised
as follows:
• Studies comparing sulfasalazine versus placebo (Ewe 1989;
Wenckert 1978);
• Studies comparing 5-ASAs to a no treatment control
(Caprilli 1994);
• Studies comparing 5-ASAs to placebo (Brignola 1995;
Florent 1996; Hanauer 2004; Lochs 2000; McLeod 1995;
Sutherland 1997);
• Studies comparing 5-ASAs to purine antimetabolites
(Ardizzone 2004; Hanauer 2004; Herfarth 2006; Reinisch 2010;
Savarino 2013);
• Studies comparing 5-ASAs to anti-tumour necrosis factor-
alpha antagonists (TNF- ) (Savarino 2013); and
• Studies comparing high dose (4 g/day) 5-ASA to low dose
(2.4 g/day) 5-ASA (Caprilli 2003).
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Outcomes
Outcome datawhere reported atmultiple time points in six studies
(Ewe 1989; Florent 1996; Herfarth 2006; Lochs 2000; McLeod
1995; Wenckert 1978), and at a single time point in eight stud-
ies (Ardizzone 2004; Brignola 1995; Caprilli 1994; Caprilli 2003;
Hanauer 2004; Reinisch 2010; Savarino 2013; Sutherland 1997).
We disregarded follow-up data in studies which continued tomon-
itor participants beyond the end of treatment.
Studies reported the following outcomes:
Primary outcome
Thirteen studies included clinical relapse as the primary outcome
(Ardizzone 2004; Brignola 1995; Caprilli 1994; Caprilli 2003;
Ewe 1989; Hanauer 2004; Herfarth 2006; Lochs 2000; McLeod
1995; Reinisch 2010; Savarino 2013; Sutherland 1997; Wenckert
1978).
Secondary outcomes
Secondary outcomes reported in the primary studies include the
following:
1) Endoscopic recurrence (Brignola 1995; Hanauer 2004; Lochs
2000);
2) Endoscopic and/or radiological recurrence combined (McLeod
1995);
3) Radiological relapse (Hanauer 2004; Savarino 2013);
4) Surgical relapse (Ardizzone 2004);
5) Adverse events (Ardizzone 2004; Brignola 1995; Caprilli 1994;
Caprilli 2003; Florent 1996; Hanauer 2004; Herfarth 2006;
McLeod 1995; Reinisch 2010; Savarino 2013; Wenckert 1978);
6) Serious adverse events (Ardizzone 2004; Hanauer 2004; Lochs
2000; McLeod 1995; Reinisch 2010);
7) Withdrawal due to adverse events (Ardizzone 2004; Brignola
1995; Caprilli 1994; Caprilli 2003; Florent 1996; Hanauer 2004;
Herfarth 2006; McLeod 1995; Reinisch 2010; Savarino 2013;
Wenckert 1978); and
8) HRQoL (Reinisch 2010; Savarino 2013; Sutherland 1997).
Funding and declaration of interest
Seven studies reported support from pharmaceutical companies
(Caprilli 1994; Caprilli 2003; Florent 1996; Hanauer 2004;
Herfarth 2006; Reinisch 2010; Sutherland 1997), but only one
study included a declaration of conflicts of interest (Reinisch
2010). The study authors were contacted to clarify the role of these
pharmaceutical companies: the authors of two studies confirmed
that the companies had no role in the study design, data analysis or
writing of the paper (Hanauer 2004; Sutherland 1997), whereas
the remaining authors did not respond. Funding and conflict of
interest was not reported in four studies (Ardizzone 2004,Brignola
1995; Ewe 1989; Lochs 2000), but our attempts to clarify this by
contacting the authors were unsuccessful.
Excluded studies
Nine studies were excluded for various reasons. These studies are
listed in Characteristics of excluded studies table and summarised
as follows:
• Four were classified as non-randomised controlled trials
(Dumois 2001; Ewe 1981; McLeod 1997; Orlando 2012);
• Four trials did not meet intervention inclusion criteria
(ISRCTN84003996; NCT00225810; NCT00245505;
NCT00300118); and
• One clinical trial was terminated due to the lack of accrual
(NCT01696942).
Risk of bias in included studies
Risk of bias was assessed using the Cochrane risk of bias tool
(Higgins 2011). The risk of bias was assessed as ’low’ in one study
(McLeod 1995), ’unclear’ in seven (Brignola 1995; Caprilli 2003;
Hanauer 2004; Lochs 2000; Reinisch 2010; Sutherland 1997;
Wenckert 1978), and as ’high’ in rest of the studies (Ardizzone
2004; Caprilli 1994; Ewe 1989; Florent 1996; Herfarth 2006;
Savarino 2013). Details of the risk of bias assessment for each
study are presented in the Characteristics of included studies and
Figure 2, and are summarised below.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item of included study.
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Allocation
Random sequence generation
In all the included studies allocation of participants to an ac-
tive treatment, no treatment or placebo was reported as random.
Eleven studies reported sufficient information regarding random
sequence generation and were judged as being at low risk of bias
for this item (Ardizzone 2004; Caprilli 1994; Ewe 1989; Hanauer
2004; Herfarth 2006; Lochs 2000;McLeod 1995; Reinisch 2010;
Savarino 2013; Sutherland 1997; Wenckert 1978). The method
of randomisation was not adequately described in three studies
(Brignola 1995; Caprilli 1994; Florent 1996) and were judged as
being at an unclear risk of bias. None of the studies was judged as
having a high risk of bias for random sequence generation.
Allocation concealment
Allocation concealment was initially graded adequate and of low
risk of bias in five studies (Caprilli 2003; Hanauer 2004; Herfarth
2006; Savarino 2013; Sutherland 1997), and unclear in the rest.
The authors of these studies were contacted to clarify allocation
concealment, but only one response was received. The response
was from Dr. McLeod, who gave further information to confirm
her study had adequate allocation concealment, hence later rated
as ’low’ (McLeod 1995). The rest of the studies were assessed
as having an inadequate description for allocation concealment,
and were marked ’unclear’ regarding risk of bias for allocation
concealment (Ardizzone 2004; Brignola 1995; Caprilli 1994; Ewe
1989; Florent 1996; Lochs 2000; Reinisch 2010;Wenckert 1978).
Blinding
Blinding of participants and personnel
Three of the studies included had an open-label study design and
were judged as being at high risk of bias for blinding (Ardizzone
2004; Caprilli 1994; Savarino 2013). All the remaining studies
were described as double-blind. However, the method of blinding
was not described clearly in four studies and these studies were
marked as ’unclear’ risk of bias (Caprilli 2003; Florent 1996;
Hanauer 2004; Wenckert 1978). These studies either failed to
reportwhich partieswere blinded or did not report that the placebo
was identical to the intervention. Due to the adequate description
of blinding methods for both participants and personnel, seven
studies were rated as having low risk of bias (Brignola 1995; Ewe
1989; Herfarth 2006; Lochs 2000;McLeod 1995; Reinisch 2010;
Sutherland 1997).
Blinding of outcome assessment
One study was judged as having high risk of detection bias as
outcome assessors were aware of treatment assignment, which was
confirmed by the lead author (Ewe 1989). Six studies were judged
as unclear risk of bias, having failed to adequately describe blinding
of outcome assessors (Ardizzone 2004; Florent 1996; Reinisch
2010; Savarino 2013; Sutherland 1997; Wenckert 1978). The
remaining seven studies reported sufficient information regarding
methods of outcome assessment blinding in order to be judged
’low risk’ for detection bias (Brignola 1995; Caprilli 1994; Caprilli
2003;Hanauer 2004;Herfarth2006; Lochs 2000;McLeod 1995).
Incomplete outcome data
Twelve studies were judged as ’low risk’ of bias. Eleven stud-
ies reported attrition rates that were low and balanced across
groups (Ardizzone 2004; Brignola 1995; Caprilli 1994; Caprilli
2003; Florent 1996; Hanauer 2004; Lochs 2000; McLeod 1995;
Reinisch 2010; Savarino 2013; Wenckert 1978), and in one study
(Ewe 1989), although the overall attrition rate was high (37%),
when compared to the event risk (60%), it was not sufficient to
introduce bias. One study was judged to be at high risk of attrition
bias due to a high discontinuation rate of 51% (Herfarth 2006).
Sutherland 1997 was judged to be at ’unclear’ risk of bias as attri-
tion rates were not specifically reported for the sub-population of
interest.
Selective reporting
None of the studies had a protocol or trial registration on
www.clinicaltrials.gov or the WHO ICTRP with the exception
of Reinisch 2010. Ten studies were judged as being at low risk
of bias for reporting all outcomes prespecified in the methods
section of the published manuscripts (Ardizzone 2004; Brignola
1995; Caprilli 1994; Caprilli 2003; Hanauer 2004; Lochs 2000;
McLeod 1995; Reinisch 2010; Savarino 2013; Sutherland 1997).
Two studies were judged to be at ’high’ risk of bias: one study failed
to report on a prespecified outcome (Florent 1996); and the other
study failed to report data on adverse events (Ewe 1989), which
is considered a key outcome for a study of this type. Wenckert
1978 was judged ’unclear’ as the results for adverse events were not
reported clearly enough to allow analysis and permit a judgement.
Herfarth 2006 was judged as ’unclear’ because it was published as
an abstract and as a letter and sufficient details about pre-specified
outcomes were not available.
Other potential sources of bias
Twelve studies were judged as being at low risk of bias as there
was no indication of other biases occurring (Ardizzone 2004;
Brignola 1995; Caprilli 1994; Caprilli 2003; Ewe 1989; Florent
1996; Hanauer 2004; Lochs 2000;McLeod 1995; Reinisch 2010;
Savarino 2013; Sutherland 1997).Wenckert 1978 was judged ’un-
clear’ for failing to provide sufficient baseline characteristics of
randomised patients, so the presence of any potential imbalances
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between groups remained uncertain. Herfarth 2006 was judged
as ’unclear’ because it was published as an abstract and as a letter
and sufficient details about other potential sources of bias were
not described.
The risk of bias data as summary percentages across all included
studies are presented in Figure 3.
Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison 5-ASA
compared to no treatment for maintenance of surgically-induced
remission in Crohn’s disease; Summary of findings 2 5-ASAs
compared to placebo for maintenance of surgically-induced
remission in Crohn’s disease; Summary of findings 3 High
dose 5-ASA compared to low dose 5-ASA for maintenance
of surgically-induced remission in Crohn’s disease; Summary
of findings 4 5-ASA compared to purine antimetabolites for
maintenance of surgically-induced remission in Crohn’s disease;
Summary of findings 5 5-ASAs compared to anti TNF- for
maintenance of surgically-induced remission in Crohn’s disease;
Summary of findings 6 Sulphasalazine compared to placebo for
maintenance of surgically-induced remission in Crohn’s disease
Detailed information regarding interventions, treatments and key
outcome definitions are presented on Table 2 and summarised
below.
5-ASA versus no treatment
Caprilli 1994 was the only study that compared 5-ASA (2.4 g/
day) to no treatment and a meta-analysis was not performed (110
participants; start of intervention: 0-2 weeks after surgery).
Primary outcome
Clinical relapse at 12 months was defined as a CDAI > 150, and
a 100 point increase in CDAI from baseline. Thirty-six percent
(20/55) of participants in the 5-ASA group relapsed at 12 months
compared to 51% (28/55) in the no treatment control group (RR
0.71, 95% CI 0.46 to 1.10, 110 participants, low certainty ev-
idence; See Analysis 1.1 and Summary of findings for the main
comparison).
Secondary outcomes
Adverse events
The effects of 5-ASAs on adverse events and withdrawal due to
adverse events compared to no treatment was uncertain (Analysis
1.2; Summary of findings for the main comparison). During the
24 month of intervention, 4% (2/55) of participants experienced
adverse events classified as adverse reactions to mesalazine (skin
rash, epigastric pain, vomiting, nausea) and they were withdrawn
from the trial, compared to 0% (0/55) in the no treatment group
(RR 5.00, 95% CI 0.25 to 101.81, 110 participants, 1 study; very
low certainty evidence).
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This study did not report on endoscopic recurrence, radiologic
relapse, serious adverse events and HRQoL.
5-ASA versus placebo
Six studies (856 participants; start of intervention: < 8 weeks after
surgery) comparing 5-ASAs (3 to 4 g/day) to placebo were iden-
tified (Brignola 1995; Florent 1996; Hanauer 2004; Lochs 2000;
McLeod 1995; Sutherland 1997).
Primary outcome
Five studies reported on clinical relapse. However, the definition
of relapse varied across the studies from CDAI > 150 (Brignola
1995; Sutherland 1997), to CDAI ≥ 250 or CDAI ≥ 200 with
a minimum of 60 points increase for 2 weeks in Lochs 2000, a
clinical recurrence score > 2 as defined by Hanauer 2004, to severe
symptoms that warrant treatment plus radiological or endoscopic
evidence of disease (McLeod 1995). There was moderate certainty
evidence that 5-ASAs are more effective than placebo for prevent-
ing clinical relapse (Analysis 2.1, Summary of findings 2). During
a follow-up period that ranged from 48 weeks to 72 months, 36%
(131/361) of 5-ASA participants relapsed compared to 43% (160/
369) of the placebo participants (RR 0.83, 95% CI 0.72 to 0.96,
730 participants, 5 studies, I² = 0%; moderate certainty evidence).
Secondary outcomes
Endoscopic recurrence
Endoscopic recurrence datawere available for three studies. Florent
1996 defined endoscopic recurrence as a Rutgeerts score i ≥ 1.
Lochs 2000 defined endoscopic recurrence as a Rutgeerts score i
≥ 2. Brignola 1995 defined endoscopic recurrence as a Rutgeerrts
score i > 2. The effect of 5-ASAs on endoscopic remission was
uncertain (Analysis 2.2, Summary of findings 2). After 12 weeks
to 72 months of follow-up, 70% (183/263) of participants treated
with 5-ASA had endoscopic recurrence compared to 73% (199/
274) in the placebo arm (RR 0.83, 95% CI 0.56 to 1.24, 537
participants, 3 studies, I² = 84%; very low certainty evidence).
Hanauer 2004 reported no difference in endoscopic recurrence
rates (i ≥ 2) between the mesalamine (48%; 95% CI 30% to
70%) and placebo (42%; 95% CI 21% to 70%) groups at 24
months (reported: HR 1.10; 84 participants). However, the data
were insufficient to be included in the meta-analysis.
The effect of 5-ASAs on radiologic relapse, adverse events, serious
adverse events andwithdrawals due to adverse eventswas uncertain
(Summary of findings 2).
Radiologic relapse
Radiologic relapse rate defined as a radiographic recurrence grad-
ing score ≥2 was reported in Hanauer 2004. After 24 months,
46% (95% CI, 29% to 66%) of participants treated with 5-ASA
had radiologic relapse compared to 49% (95%CI, 30% to 72%) in
the placebo group (reported: HR 0.61; 84 participants). McLeod
1995 reported combined endoscopic and radiologic relapse rate
based on the presence of endoscopic or radiological evidence of
disease in both symptomatic and asymptomatic patients. At 72
months, mesalamine was more effective in preventing endoscopic
and radiologic relapse compared to placebo (RR 0.635, 95% CI
0.44 to 0.91; 169 participants).
Adverse events, serious adverse events and withdrawal due to
adverse events
There was no clear difference in the number of participants who
experienced adverse events, serious adverse events or were with-
drawn from the trial due to adverse events when 5-ASAs were
compared to placebo. Adverse events (Analysis 2.3) were reported
in all but one study (Sutherland 1997). Ten per cent (23/241)
of 5-ASA participants experienced at least one adverse event that
was possibly related to treatment compared to 9% (20/225) of
placebo participants (RR 1.07; 95% CI 0.60 to 1.91; 466 par-
ticipants; 4 studies; I² = 0%; low certainty evidence). Reported
adverse events included skin lesions, abdominal pain, diarrhoea ,
vomiting and nausea. Three studies reported serious adverse events
that were possibly related to treatment (Hanauer 2004; Lochs
2000; McLeod 1995). Over a follow-up period of 52 weeks to 72
months, approximately an equal proportion of participants from
the 5-ASA (3%; 9/286) and the placebo (3%; 9/291) groups expe-
rienced at least one serious adverse event (RR 1.06, 95% CI 0.44
to 2.59, 577 participants, I² = 0%, See Analysis 2.4; low certainty
evidence). Reported serious adverse events included postoperative
bowel obstruction and pancreatitis. Withdrawal due to adverse
events (Analysis 2.5) was reported in three studies (Brignola 1995;
Florent 1996; Hanauer 2004). Over a follow-up period ranging
from 12 weeks to 24 months, the withdrawal rate due to adverse
events was 10% (16/153) among 5-ASA participants compared to
7% (10/144) among placebo participants (RR 1.50, 95% CI 0.71
to 3.19, 297 participants, I² =0%; low certainty evidence). Adverse
events leading to withdrawal included abdominal pain, pancreati-
tis and declining creatine clearance. McLeod 1995 reported the
total number of withdrawn participants in both intervention arms
(6/167) and as data could not be separated it was not included in
the meta-analysis.
HRQoL
Health related quality of life using the IBDQ was evaluated in one
study at week 48 (293 participants). However, there were no data
reported for further analysis (Sutherland 1997).
High dose versus low dose 5-ASA
Caprilli 2003 was the only study that compared 5-ASA in doses
of 4.0 g/day to 2.4 g/day (206 participants; start of intervention:
0 to 2 weeks after surgery).
Primary outcome
Clinical relapse was defined as a CDAI score higher than 150 or an
increase in CDAI of more than 100 points from baseline. There
was moderate certainty evidence for the efficacy of mesalamine for
maintaining clinical remission when administered in doses of 4.0
g/day and 2.4 g/day (Analysis 3.1; Summary of findings 3). At 12
months, the proportion of participants with clinical relapse was
17Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17% (17/101) among the 4 g/day mesalamine group compared
to 26% (27/105) in the 2.4 g/day group (RR 0.65, 95% CI 0.38
to 1.13, 206 participants; moderate certainty evidence).
Secondary outcomes
Endoscopic recurrence
The definition for endoscopic recurrence was based on the pres-
ence of typical endoscopic Crohn’s disease lesions in the terminal
ileum or anastomosis, graded on the Rutgeer’s score > 1. There
was moderate certainty evidence regarding the effects of 4.0 g/
day compared to 2.4 g/day mesalamine treatment for prevention
of endoscopic recurrence (Analysis 3.2; Summary of findings 3).
After 12 months, the proportion of participants with endoscopic
recurrence was 45% (45/101) and 56% (59/105) in the 4.0 g/day
and 2.4 g/day mesalamine treated participants respectively (RR
0.79, 95% CI 0.60 to 1.04, 206 participants; moderate certainty
evidence).
Adverse events, serious adverse events and withdrawal due to
adverse events
Regarging adverse events and withdrawal due to adverse events,
the evidence was low certainty (Analysis 3.3; Summary of findings
3). At 12 months, approximately an equal proportion of partic-
ipants from the 4.0 g/day (2%; 2/101) and the 2.4 g/day (2%;
2/105) groups experienced an adverse event and were withdrawn
from the study (RR 1.04, 95% CI 0.15 to 7.24, 206 participants;
low certainty evidence). Reported adverse events include severe
dyspepsia, increase in transaminases and limb cramps.
Caprilli 2003 did not report on serious adverse events and
HRQoL.
5-ASA versus purine antimetabolites
A total of five studies compared the efficacy of mesalamine (dose
3 to 4 g/day) to azathioprine (Ardizzone 2004; Herfarth 2006;
Reinisch 2010; Savarino 2013), or 6-mercaptopurine (Hanauer
2004) agents (425 participants; start of intervention: within 4
weeks, except in Reinisch 2010 (6 to 24 months postoperatively)).
Due to the specific inclusion/exclusion criteria in Reinisch 2010
(Characteristics of included studies), the clinical and endoscopic
recurrence data of this study were not included in meta-analyses.
Primary outcome
Clinical relapse was reported in four studies, defined as clinical re-
currence grading score ≥ 2 in Hanauer 2004 and Savarino 2013,
as a CDAI > 150 plus a 100-point increase in CDAI from base-
line in Herfarth 2006, or CDAI ≥ 200 in Ardizzone 2004.The
effect of 5-ASA compounds in comparison to azathioprine or 6-
mercaptopurine on clinical relapse was uncertain (Analysis 4.1.;
Summary of findings 4). At the end of 24 months of treatment,
61% (103/170) of mesalamine treated participants clinically re-
lapsed compared to 67% (119/177) of azathioprine participants
(RR 0.90, 95% CI 0.76 to 1.07, 347 participants, 4 studies, I² =
38%; low certainty evidence).
Secondary outcomes
Endoscopic recurrence
Endoscopic recurrence defined as a Rugeerts score ≥ 2, was
reported in one study and meta-analysis was not performed
(Savarino 2013). The efficacy of 5-ASA in comparison to purine
antimetabolites agents for preventing endoscopic recurrence was
uncertain (Analysis 4.2; Summary of findings 4). After 24months,
83% (15/18) of 5-ASA treated participants relapsed compared to
65% (11/17) in the purine analogues group (RR 1.29, 95% CI
0.86 to 1.94; very low certainty evidence).
Radiologic relapse
Radiologic relapse defined as a radiographic recurrence grading
score ≥ 2, was reported in one study and meta-analysis was not
performed (Savarino 2013). The effect of 5-ASA drugs on the
radiologic relapse rate compared topurine analogues was uncertain
(Analysis 4.3). At 24 months, 83% (15/18) of 5-ASA participants
experienced radiologic relapse compared to 76% (13/17) of the
purine antimetabolites group (RR 1.09, 95% CI 0.78 to 1.52;
very low certainty evidence).
Endoscopic and radiologic relapse rates were reported by Hanauer
2004. However, the results lacked sufficient detail to be included
in the meta-analysis. At 24 months (91 participants), the reported
endoscopic and radiologic relapse rates were 48% (95% CI 30 to
70) and 46% (95 CI 29 to 66) in the mesalamine intervention
group compared to 16% (95% CI 7 to 35) and 33% (95% CI 19
to 54) in the purine antimetabolites group respectively.
Surgical relapse
Surgical relapse defined as the need for another surgery was re-
ported by Ardizzone 2004. The effect of 5-ASA compared to
purine analogues on surgical relapse was uncertain (Analysis 4.4).
During the follow-up period of two years, the proportion of partic-
ipants with surgical relapse was 35% (26/71) in the 5-ASA group
compared to 29% (21/71) in the purine analogues group (RR
1.24, 95% CI 0.77 to 1.98).
Adverse events, serious adverse events and withdrawal due to
adverse events
Adverse events and withdrawal due to adverse were reported in five
studies, while serious adverse events were reported in all studies ex-
cept for Savarino 2013. The effect of 5-ASA drugs on safety when
compared to the purine analogues was uncertain, as the quality of
evidence ranged from low to very low (Summary of findings 4).
During a follow-up period of 52 weeks to 24 months, the propor-
tion of 5-ASA participants who experienced at least one adverse
event (Analysis 4.5) was 52% (107/207) compared to 47% (102/
218) of purine analogue participants (RR 1.11, 95% CI 0.97 to
1.27, 425 participants, 5 studies, I² = 0%; low certainty evidence).
Reported adverse events include leukopenia, abdominal pain, nau-
sea, nasopharyngitis, diarrhoea and headache. Four per cent (6/
152) of patients treated with 5-ASA experienced serious adverse
events compared to 17% (27/159) of the purine antimetabolites
group (RR 0.30, 95%CI 0.11 to 0.80, 311 participants, 3 studies,
I² = 9%; very low certainty evidence). The types of serious adverse
events were not well described in the studies but included post-
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operative bowel obstruction and acute pancreatitis. Eight per cent
(17/207) of the 5-ASA group withdrew due to an adverse event
during 52 weeks to 24 months of follow-up compared to 19%
(42/218) of the purine analogues group (RR 0.48, 95%CI 0.28 to
0.83, 425 participants, 5 studies, I² = 0%; low certainty evidence).
Adverse events leading to withdrawal included severe epigastric
intolerance, increase in liver function test results, leukopenia, and
acute pancreatitis.
HRQoL
Two studies with treatment duration of 52 weeks and 24 months
reported on HRQoL based on the IBDQ score (Reinisch 2010;
Savarino 2013). The effect of 5-ASA agents compared to purine
analogues on HRQoL was uncertain. Savarino 2013 reported on
the proportion of participants with an IBDQ score > 170 which is
regarded as a symptomatic remission score (IBDQ scores ranged
from 32 to 224). At 24 months of follow-up (Analysis 4.8), 17%
(3/18) of 5-ASA treated participants reported an IBDQ score >
170 compared with 12% (2/17) in the azathioprine group (RR
1.42, 95% CI 0.27 to 7.46; very low certainty evidence). Reinisch
2010, assessedHRQoL based on themean change in IBDQ scores
compared to baseline (Analysis 4.9). Themeandifference in IBDQ
score at 52 weeks compared to baseline among the 5-ASA treated
group was 5 (SD 27.4) compared to 9 (SD 17.7) in the purine
analogue group (MD -4.00, CI -14.36 to 6.36; 78 participants).
5-ASAs vs anti-TNF-
One study (34 participants; start of intervention: 2 to 4weeks after
surgery) comparedmesalamine (3 g/day) to adalimumab (Savarino
2013). The effect of mesalamine in comparison to adalimumab
on preventing postoperative clinical, endoscopic and radiologic
recurrence was uncertain (Summary of findings 5).
Primary outcome
Clinical relapse was defined as clinical recurrence grading score ≥
2 (Analysis 4.1). Over 24 months of follow-up, 50% (9/18) of 5-
ASA participants had clinical relapse compared to 12% (2/16) in
the anti TNF- intervention (RR 4.00, 95% CI 1.01 to 15.84;
very low certainty evidence).
Secondary outcomes
Endoscopic and radiologic recurrence
Endoscopic recurrence was defined as Rutgeert’s score ≥ 2
(Analysis 5.2), while radiologic relapse was defined as a radio-
graphic recurrence score ≥2 (Analysis 5.3). The proportions of
participants with endoscopic and radiologic recurrence within the
mesalamine and adalimumab groups were equal. Namely, 83%
(15/18) of mesalamine treated participants and 6% (1/16) of adal-
imumab participants had both endoscopic and radiologic recur-
rence after a follow-up of 24 months (RR 13.33, 95% CI 1.98 to
89.95; very low certainty evidence for both outcomes).
Adverse events, serious adverse events and withdrawal due to
adverse events
The effect of oral 5-ASA compounds compared to anti TNF-
on adverse events (Analysis 5.4), and withdrawal due to adverse
events (Analysis 5.5), was uncertain (Summary of findings 5).
After 24 months, the proportion of participants who experienced
adverse events in the 5-ASA group was 78% (14/18) compared
to the 69% (11/16) of the adalimumab group (RR 1.13, 95% CI
0.75 to 1.71; very low certainty evidence). Reported adverse events
include bronchitis, nasopharyngitis, abdominal pain, arthralgia
and exacerbation of Crohn’s disease.Over 24months of follow-up,
0% (0/18) of 5-ASA participants withdrew from the study due to
adverse events compared to 6% (1/16) of adalimumab participants
(RR 0.30, 95% CI 0.01 to 6.84; very low certainty evidence).
Adverse events leading to withdrawal included atopic dermatitis
and severe exacerbation of Crohn’s disease.
HRQoL
The effect of 5-ASA compared to adalimumab on HRQoL was
uncertain (Analysis 5.6; Summary of findings 5). At 24 months,
an IBDQ > 170 was reported in 17% (3/18) of 5-ASA participants
compared to 88% (14/16) of adalimumab participants (RR 0.19,
95% CI 0.07 to 0.54; very low certainty evidence).
Sulphasalazine versus placebo
There were two studies (298 participants; start of intervention: 0
to 4 weeks after surgery) that compared sulphasalazine (3 g/day)
with placebo (Ewe 1989; Wenckert 1978).
Primary outcome
Clinical relapse defined as ’proven radiological, endoscopic or op-
eration findings’ (Ewe 1989), or as a scoring system developed for
the study that considered symptoms, signs and impact (Wenckert
1978), was reported in both studies. The effect of sulphasalazine
compared to placebo for maintaining surgically-induced remis-
sion in Crohn’s disease is uncertain due to low certainty evidence
(Analysis 6.1; Summary of findings 6). After 18 to 36 months of
follow-up, 66% (95/143) of sulphasalazine participants relapsed
compared with 71% (110/155) of placebo participants (RR 0.88,
95% CI 0.56 to 1.38, I² = 38%; low certainty evidence).
Secondary outcomes
The certainty of the evidence regarding adverse events of sul-
phasalazine is very low (Analysis 6.2, Summary of findings 6).
Adverse events were reported only in Wenckert 1978 and meta-
analysis was not performed. After 18 months of follow-up, one
participant belonging to the placebo group (3%; 1/34) experi-
enced nausea caused by a parallel consumption of acetylsalicylic
acid and was withdrawn from the study, compared to none in the
sulphasalazine group (0%; 0/32) (RR 0.35, 95% CI 0.01 to 8.38;
very low certainty evidence).
Endoscopic recurrence, radiological relapse, adverse events, serious
adverse events and HRQoL were not reported on in either study.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
5-ASAs compared to placebo for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: people with surgically-induced remission in Crohn’s disease
Setting: outpat ients
Intervention: 5-ASA (3 to 4 g/ day)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with 5-ASA
Clinical relapse
Follow-up: 48 weeks to
72 months
434 per 1,000 360 per 1,000
(312 to 416)
RR 0.83
(0.72 to 0.96)
730
(5 studies)
⊕⊕⊕©
MODERATE 1
Clinical relapse def ined
as CDAI >150 (Brignola
1995; Sutherland 1997)
; CDAI ≥ 250 (Lochs
2000); clinical recur-
rence score > 2 (
Hanauer 2004); severe
symptoms that warrant
treatment plus radio-
logical/ endoscopic evi-
dence (McLeod 1995)
Endoscopic recurrence
Follow-up:12 weeks to
72 months
726 per 1,000 603 per 1,000
(407 to 901)
RR 0.83
(0.56 to 1.24)
537
(3 studies)
⊕©©©
VERY LOW 23
Enodscopic recurrence
def ined as Rutgeerts
score i ≥1 (Florent
1996), Rutgeerts score
i ≥ 2 (Lochs 2000),
Rutgeerrts score i > 2
(Brignola 1995)
Radiologic relapse Outcome not reported Not reported
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Adverse events
Follow-up:12 weeks to
72 months
89 per 1,000 95 per 1,000
(53 to 170)
RR 1.07
(0.60 to 1.91)
466
(4 studies)
⊕⊕©©
LOW 3
Reported adverse
events included skin le-
sions, abdominal pain,
diarrhea , vomit ing and
nausea
Serious adverse events
Follow-up:48 weeks to
72 months
31 per 1,000 33 per 1,000
(14 to 80)
RR 1.06
(0.44 to 2.59)
577
(3 studies)
⊕⊕©©
LOW 4
Reported serious ad-
verse events included
postoperat ive bowel
obstruct ion and pancre-
at it is
Withdrawal due to ad-
verse events
Follow-up:12 weeks to
72 months
69 per 1,000 104 per 1,000
(49 to 222)
RR 1.50
(0.71 to 3.19)
297
(3 studies)
⊕⊕©©
LOW 5
Adverse events leading
to withdrawal included
abdominal pain, pan-
creat it is and declining
creat ine clearance
Health related quality
of life
Outcome not reported Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious imprecision (291 events)
2 Downgraded one level due to high risk of report ing bias and unclear risk of select ion bias and outcome assessment
3 Downgraded two levels due to substant ial heterogeneity ( I² = 84%)
4 Downgraded two levels due to very serious imprecision (43 events)
5 Downgraded two levels dur to due to very serious imprecision (18 events)21
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6 Downgraded two levels due to very serious imprecision (26 events)
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High compared to low dose 5-ASAs for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: people with surgically-induced remission in Crohn’s disease
Setting: outpat ient
Intervention: high dose 5-ASAs (4.0 g/ day)
Comparison: low dose 5-ASAs (2.4 g/ day)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with low dose 5-
ASA
Risk with high dose 5-
ASA
Clinical relapse
Follow-up:12 months
257 per 1,000 167 per 1,000
(98 to 291)
RR 0.65
(0.38 to 1.13)
206
(1 RCT)
⊕⊕⊕©
MODERATE 1
Clinical relapse re-
ported as CDAI > 150 or
increase of 100 points
f rom baseline (Caprilli
2003)
Endoscopic recurrence
Follow-up:12 months
562 per 1,000 444 per 1,000
(337 to 584)
RR 0.79
(0.60 to 1.04)
206
(1 RCT)
⊕⊕⊕©
MODERATE 2
Endoscopic recurrence
reported as Rutgeer’s
score >1 (Caprilli 2003)
Radiologic relapse Outcome not reported Not reported
Adverse events
Follow-up:12 months
19 per 1,000 20 per 1,000
(3 to 138)
RR 1.04
(0.15 to 7.24)
206
(1 RCT)
⊕⊕©©
LOW 3
Reported
adverse events include
severe dyspepsia, in-
crease in transami-
nases and limb cramps
Serious adverse events Outcome not reported Not reported
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Withdrawal due to ad-
verse events
Follow-up: 12 months
19 per 1,000 20 per 1,000
(3 to 138)
RR 1.04
(0.15 to 7.24)
206
(1 RCT)
⊕⊕©©
LOW 3
Reported
adverse events include
severe dyspepsia, in-
crease in transami-
nases and limb cramps
Health related quality
of life
Outcome not reported Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious imprecision (44 events)
2 Downgraded one level due to due to serious imprecision (104 events)
3 Downgraded two levels due to due to very serious imprecision (4 events)
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5-ASA compared to purine antimetabolites for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: people with surgically-induced remission in Crohn’s disease
Setting: outpat ient
Intervention: 5-ASA (3-4 g/ day)
Comparison: purine ant imetabolites
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with purine an-
timetabolites
Risk with 5-ASA
Clinical relapse
Follow-up:24 months
672 per 1,000 605 per 1,000
(511 to 719)
RR 0.90
(0.76 to 1.07)
347
(4 studies)
⊕⊕©©
LOW 12
Clinical relapse def ined
as a clinical grad-
ing score ≥ 2 (
Hanauer 2004;Savarino
2013) CDAI ≥ 200 (
Ardizzone 2004)
CDAI > 200 plus a 100-
point increase in CDAI
f rom baseline (Herfarth
2006)
Endoscopic recurrence
Follow-up:24 months
647 per 1,000 835 per 1,000
(556 to 1,000)
RR 1.29
(0.86 to 1.94)
35
(1 study)
⊕©©©
VERY LOW 13
Endoscopic recurrence
def ined as Rugeerts
score ≥ 2 (Savarino
2013)
Radiologic relapse
Follow-up:24 months
765 per 1,000 834 per 1,000
(596 to 1,000)
RR 1.09
(0.78 to 1.52)
35
(1 study)
⊕©©©
VERY LOW 14
Radiologic relapse de-
f ined as a radiographic
grading score ≥ 2 (
Savarino 2013)
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Adverse events
Follow-up:52 weeks-24
months
468 per 1,000 519 per 1,000
(454 to 594)
RR 1.11
(0.97 to 1.27)
425
(5 studies)
⊕⊕©©
LOW 15
Reported
adverse events in-
cluded leukopenia, ab-
dominal pain, nausea,
nasopharyngit is, diar-
rhoea.and headache
Serious adverse events
Follow-up:52 weeks to
24 months
170 per 1,000 51 per 1,000
(19 to 136)
RR 0.30
(0.11 to 0.80)
311
(3 studies)
⊕©©©
VERY LOW 16
Reported serious ad-
verse events included
postoperat ive bowel
obstruct ion and pancre-
at it is
Withdrawal due to ad-
verse events
Follow-up:52 weeks to
24 months
193 per 1,000 92 per 1,000
(54 to 160)
RR 0.48
(0.28 to 0.83)
425
(5 studies)
⊕⊕©©
LOW 17
Adverse events leading
to withdrawal included
severe epigastric intol-
erance, increase in liver
funct ion test results,
leukopenia, acute pan-
creat it is
Health related quality
of life
Follow-up: 24 months
1118 per 1,000 167 per 1,000
(32 to 878)
RR 1.42
(0.27 to 7.46)
35
(1 study)
⊕©©© 18
VERY LOW
Health related quality
of lif e def ined as IBDQ
score > 170
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to to high risk of performance bias26
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2 Downgraded one level due to serious imprecision (222 events)
3 Downgraded two levels due to serious imprecision (26 events)
4 Downgraded two levels due to serious imprecision (28 events)
5 Downgraded one level due to serious imprecision (209 events)
6 Downgraded two levels due to very serious imprecision (33 events)
7 Downgraded one level due to serious imprecision (59 events)
8 Downgraded two levels due to very serious imprecision (5 events)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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5-ASAs compared to anti TNF- for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: people with surgically-induced remission in Crohn’s disease
Setting: outpat ient
Intervention: 5-ASAs (3 g/ day)
Comparison: ant i TNF-
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with anti TNF- Risk with 5-ASAs
Clinical relapse
Follow-up: 24 months
126 per 1,000 500 per 1,000
(126 to 1,000)
RR 4.00
(1.01 to 15.84)
34
(1 study)
⊕©©©
VERY LOW 12
Clinical relapse def ined
as a grading score ≥ 2
(Savarino 2013)
Endoscopic recurrence
Follow-up: 24 months
63 per 1,000 833 per 1,000
(124 to 1,000)
RR 13.33
(1.98 to 89.95)
34
(1 study)
⊕⊕©©
VERY LOW 13
Endoscopic recurrence
def ined as a Rutgeert ’s
score ≥2 (Savarino
2013)
Radiologic relapse
Follow-up: 24 months
63 per 1,000 833 per 1,000
(124 to 1,000)
RR 13.33
(1.98 to 89.95)
34
(1 study)
⊕©©©
VERY LOW 13
Radiologic relapse de-
f ined as a score ≥2
(Savarino 2013)
Adverse events
Follow-up: 24 months
688 per 1,000 777 per 1,000
(516 to 1,000)
RR 1.13
(0.75 to 1.71)
34
(1 study)
⊕⊕©©
VERY LOW 14
Re-
ported adverse events
included bronchit is, na-
sopharyngit is, abdomi-
nal pain, arthralgia and
exacerbat ion of Crohn’s
disease
Serious adverse events Outcome not reported Not reported
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Withdrawal due to ad-
verse events
Follow-up: 24 months
63 per 1,000 19 per 1,000
(0 to 428)
RR 0.30
(0.01 to 6.84)
34
(1 study)
⊕©©©
VERY LOW 15
Adverse events leading
to withdrawal included
atopic dermatit is and
severe exacerbat ion of
Crohn’s disease
Health related quality
of life
Follow-up: 24 months
875 per 1,000 166 per 1,000
(61 to 473)
RR 0.19
(0.07 to 0.54)
34
(1 study)
⊕©©©
VERY LOW 16
Health related quality of
lif e def ined as (IBDQ
>170)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high risk of performance bias and unclear risk of outcome assessment bias
2 Downgraded two levels due to very serious imprecision (10 events)
3 Downgraded two levels due to very serious imprecision (16 events)
4 Downgraded two levels due to very serious imprecision (25 events)
5 Downgraded two levels due to very serious imprecision (1 event)
6 Downgraded two levels due to very serious imprecision( 17 events)
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Sulphasalazine compared to placebo for maintenance of surgically- induced remission in Crohn’s disease
Patient or population: people with surgically-induced remission in Crohn’s disease
Setting: outpat ient
Intervention: Sulphasalazine (3 g/ day)
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with Placebo Risk with
Sulphasalazine
Clinical relapse
Follow-up:18 to 36
months
710 per 1,000 625 per 1,000
(397 to 979)
RR 0.88
(0.56 to 1.38)
298
(2 studies)
⊕⊕©©
LOW 12
Clinical relapse was
proven by radiological,
endoscopic, or oper-
at ion f indings (Ewe
1989)
Clinical relapse was
measured by a scor-
ing system that consid-
ered symptoms, signs
and impact (Wenckert
1978)
Endoscopic recurrence Outcome not reported Not reported
Radiologic relapse Outcome not reported Not reported
Adverse events Outcome not reported Not reported
Serious adverse events Outcome not reported Not reported
Withdrawal due to ad-
verse events
Follow-up:18 months
29 per 1,000 10 per 1,000
(0 to 246)
RR 0.35
(0.01 to 8.38)
66
(1 RCT)
⊕©©©
VERY LOW 34
Adverse events leading
to withdrawal included
nausea
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Health related quality
of life (HRQL)
Outcome not reported Not reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the median risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for lim itat ion due to high risk of report ing and detect ion bias
2 Downgraded one level due to serious imprecision (205 events)
3 Downgraded one level due to unclear risk of bias for several domains
4 Downgraded two levels due to very serious imprecision (1 event)
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D I S C U S S I O N
Summary of main results
This updated review includes 14 studies (1867 participants) in-
vestigating the use of 5-ASA agents for maintenance of remission
in Crohn’s disease after surgery. Sulphasalazine agents, the earliest
class of 5-ASA drug, have not shown efficacy compared to placebo
for preventing clinical relapse (low certainty evidence), although
there were just two older studies for this comparison. Similarly
for 5-ASA versus no treatment, efficacy was not demonstrated,
although again there was just a small number of participants in
one study. Both of these results were judged to be of low certainty
evidence due to quality issues and imprecision.
5-ASA agents when compared with placebo were efficacious for
the prevention of clinical relapse and this result was rated as mod-
erate certainty evidence on GRADE analysis, with five studies in-
cluded in this analysis. The number needed to treat to prevent one
relapse was 13. Endoscopic recurrence was not as consistently re-
ported with only three studies included in the analysis. The effect
of 5-ASA on endoscopic recurrence is uncertain due to very low
certainty evidence due to substantial heterogeneity and high risk
of bias.
5-ASA agents compared topurine analogueswere also investigated.
There was no difference between 5-ASA agents and purine ana-
logues in preventing clinical relapse, although this outcome was
reported as low certainty evidence due to risk of bias and impreci-
sion. The secondary outcome of preventing endoscopic recurrence
was also analysed and no difference in efficacy between the agents
was found, however this outcome was rated as very low certainty
evidence due to a high risk of bias and very serious imprecision.
A single study compared two different dosing regimens of the same
5-ASA agent (4 g/day versus 2.4 g/day), but found no difference in
preventing clinical relapse.The certainty of evidence was reported
as moderate due to imprecision from the small event numbers.
One study compared 5-ASA with an anti TNF- agent (adali-
mumab) and found 5-ASA to be inferior compared to adalimumab
for prevention of clinical relapse.However, this outcome was rated
as very low certainty evidence due to risk of bias and very serious
imprecision.
The effect of 5-ASA on adverse events was uncertain. The overall
certainty of the evidence for adverse event outcomes ranged from
very low to low due to serious imprecision and high risk of bias. 5-
ASA did not appear to increase the risk of adverse events, serious
adverse events or withdrawal due to adverse events when compared
with placebo, no treatment or adalimumab. 5-ASA participants
had fewer serious adverse events and withdrawals due to adverse
events than participants who received purine antimetabolites.
5-ASA preparations are ineffective for maintenance of medically-
induced remission in Crohn’s disease (Akobeng 2016). It is not
clear why the evidence suggests a difference in efficacy for 5-ASA
agents in patients with medically- and surgically-induced remis-
sion. One possibility could be that disease activity levels at study
entry may not be comparable. The limitations of a CDAI score
within clinical trials has previously been noted (Caprilli 1994),
and most of the clinical trials performed to evaluate the role of 5-
ASA in the maintenance of medically-induced remission defined
remission using the CDAI score. As most of the trials involved
in this review used surgical resection of macroscopically diseased
bowel as inclusion criterion, it follows that many of these par-
ticipants may have less active disease at study entry compared to
participants in trials of medically-induced remission. This may
explain the observed difference in efficacy of 5-ASA agents.
It is also possible that the length of time in remission may partly
explain this difference in efficacy.Many of the studies in the review
of medically-induced remission included patients who had been
in remission for significant periods of time prior to study entry
(Akobeng 2016). By contrast, most of the studies in this review
required entry and initiation of therapywithin 12weeks of surgery.
Evidence obtained from studies with a follow-up of greater than 12
months still favoured the use of 5-ASA agents, but as the longest
study follow-upwas 36months, it is possible that if a longer follow-
up was used this effect would not be sustained.
Overall completeness and applicability of
evidence
With the increase of studies in this updated review, the overall
volume and utility of the synthesised data has improved. This has
facilitated meaningful comparisons. Moderate certainty evidence
indicates that 5-ASA is superior to placebo for maintaining sur-
gically-induced remission in Crohn’s disease. The effect of 5-ASA
on endoscopic recurrence was uncertain as the certainty of the
evidence was very low, so this would be an outcome of interest if
further studies do occur in this context.
The evidence is less complete when 5-ASA agents are compared
with the two key medication classes that are routinely considered
in the post-surgical setting (i.e. purine analogues and anti TNF-
agents). The evidence shows no difference in efficacy when 5-
ASA is compared with purine analogues. There was a difference in
safety favouring 5-ASA over purine analogues. As these results were
rated as very low or low certainty predominantly due to issues with
imprecision, this is an area that needs to be addressed. Similarly,
there is just one trial with 34 patients comparing 5-ASA with anti
TNF- agents and therefore further research is warranted.
The longest follow-up period was six years, with the majority of
trials following participants for less than three years and again this
further limits the applicability of the evidence to clinical practice.
Time-to-event data would be useful as this would allow better
insights on the efficacy of 5-ASA for preventing relapse in post-
surgical Crohn’s disease.
32Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The reporting of adverse events was a source of significant hetero-
geneity. The terminology used to describe adverse events in the
included studies was not consistent. Terms used included minor
adverse events, adverse events, side effects, major side effects, seri-
ous adverse events, serious events attributable to medication and
withdrawals due to adverse events. Across studies, the reporting
of adverse events was not consistent, with some studies reporting
total event numbers, rather than the number of events per partic-
ipants and some studies included treatment failure as an adverse
event. There is now clear guidance on the reporting of adverse
event outcomes in IBD trials and we strongly advise future studies
to align with this.
Quality of the evidence
The included studies were inconsistent in terms of quality. The
risk of bias was judged to be low in one study, unclear in seven
studies and high in six studies. For the comparison of 5-ASA to
placebo, there was moderate certainty evidence of the efficacy of 5-
ASA for preventing clinical relapse in post-surgical Crohn’s disease.
Whilst this has added to our confidence in the effect estimate,
this is not the case for other comparisons and outcomes assessed
in this review. In particular, the studies comparing 5-ASA with
purine analogues had issues with performance bias and sparse data.
Additionally, there is just one trial comparing 5-ASA with anti
TNF- agents. This led to other results being of very low or
low certainty. Nonetheless, it is worth noting that there was little
statistical heterogeneity noted across the comparisons. There was
no indirectness as the included studies were all within the scope
of the review. However, the limited number of studies precluded
an assessment of publication bias.
Potential biases in the review process
We acknowledge that there are certain decisions which were made
during the review process which may have introduced bias in the
results. It was decided that sulphasalazine as a pharmacologically
different 5-ASA should be analysed separately, a decision that was
not made for the previous version of the review. It is worth noting,
however, that if 5-ASA and sulphasalazine studies are combined,
the results do not change.
There were also significant problems classifying adverse events, as
stated above. For the purposes of maintaining as homogenous re-
porting as possible, it was decided that we would not report on
minor adverse events. Additionally, when considering the remain-
ing adverse events, disease worsening or treatment failure were re-
moved from the counting of adverse events. This was done for two
reasons. Firstly, it was of concern that such patients may have al-
ready been included in the original relapse figures and be counted
twice and whilst we tried to confirm this with authors, it was not
always possible. Secondly, it was felt that such outcomes should
be considered a natural result of treatments that do have a variable
efficacy, it was not appropriate to consider these events as adverse
events. However, it is possible such judgements may be a source
of bias.
Agreements and disagreements with other
studies or reviews
Since the original publication of this review (Gordon 2011), the
UK National Institute for Health and Care Excellance guidance
was updated to now consider 5-ASA as a treatment in this con-
text (NICE 2012). However, the most recent NICE guidelines
that were updated in May 2019 removed the recommendation
stating that 5-ASA had not been shown to be clinically or cost
effective in terms of endoscopic relapse rates (NICE 2019). How-
ever, the NICE systematic review excluded studies with less than
12 months follow-up and did not include abstracts. This led to
several studies being excluded from the NICE guideline that have
contributed to this review (Florent 1996; Herfarth 2006; Reinisch
2010; Sutherland 1997), and a reduction in the size of the evi-
dence base.
An additional concern is that the NICE systematic review used
a network meta-analysis methodology. However, several included
studies that exerted influence on the network included non-ran-
domised active agents, specifically metronidazole. This does not
meet the stringent requirement of transitivity for network meta-
analysis and therefore limits the conclusions that can bemade from
the NICE meta-analysis.
The most recent American Gastroenterological Association guide-
line does not recommend the use of 5-ASA in this setting, citing
the low GRADE rating on their committee analysis and so this re-
view is not in agreement with this guideline (Nguyen 2017). The
European Crohn’s and Colitis Organisation guidelines are older
and include far fewer studies in their analysis, but conclude that
while 5-ASA is effective, it is less effective than purine analogues
with no difference in safety (Van Assche 2010). This is also in
contrast with the findings of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate certainty evidence suggests that 5-ASA preparations are
superior to placebo for themaintenance of surgically-induced clin-
ical remission inpatientswithCrohn’s disease. The number needed
to treat to prevent one relapse was 13 patients. However, the effect
of 5-ASA on endoscopic remission was uncertain. These findings
require careful consideration given that endoscopic recurrence has
been shown to precede clinical relapse. There was no evidence of
a difference in the rate of adverse events, serious adverse events or
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withdrawals in the 5-ASA or placebo groups, but this was rated
as low certainty evidence. The analysis of the studies comparing
sulphasalazine to placebo did not demonstrate superiority, but this
result was of low or very low certainty due to sparse data and risk
of bias. This was also the case for the one study that compared 5-
ASA with no treatment. There was no difference between 5-ASA
(mesalamine) and purine analogues (azathioprine) in efficacy, but
there was evidence of lower rates of serious adverse events and
withdrawals due to adverse events with 5-ASA agents. However,
the evidence was rated as low or very low certainty. Finally, in one
study 5-ASA was inferior to anti TNF- agents, although the
evidence was rated as very low certainty.
Implications for research
Further studies investigating the efficacy of 5-ASA for mainte-
nance of endoscopic remission may be required. However, given
that the current international guidance recommends post-surgical
prophylaxis over no intervention (Nguyen 2017), it is proposed
that further studies would be best placed to investigate both en-
doscopic and clinical outcomes for 5-ASA when compared with
purine analogues and anti TNF- . Key to these studies is the need
to address both design and reporting issues that have been iden-
tified in both versions of this review, as well as enrolling enough
participants to allow for adequate statistical power.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ardizzone 2004
Methods Study design: RCT, single centre
Setting: University “L.Sacco” Hospital (Milan, Italy), 1994-2001
Participants Inclusion:
Adult (18-70yrs) patients who underwent surgery for symptomatic intestinal stenosis or
occlusion, which is clinically quiescent (CDAI ≤ 150
CD) able to start oral nutrition and oral medication within the first 2 postoperative
weeks
Exclusion:Contraindications for use ofmesalamine or AZA and pre-existing hepatic dis-
ease, renal dysfunction, clinically important lung disease, systemic infection, short-bowel
syndrome, presence of alcoholic stoma, history of cancer, hypersensitivity to mesalamine
or AZA, erythrocytemacrocytosis, use of immunosuppressive drugs in the past 3months;
patients who had received treatment with anti-TNF α within the 6 months before
surgery; pregnancy/breastfeeding; patients who had undergone surgical procedures other
than conservative surgery or for perianal disease only; history of corticosteroid-depen-
dent disease
Age (IG1 / IG2)mean: 38.4 yrs mean overall
Sex (M:F): 95: 52 overall; (45:26) vs. (50:26)
Type of surgery: Stricturoplasty- 36; Minimal bowel resection- 70; Minimal bowel
resection stricturoplasty-36
Previous surgery (IG1+IG2): 69/142 overall (38/71) vs. (31/71)
Start of intervention after surgery: <2 weeks
Medication use (IG1+ IG2): Mesalamine or sulphasalazine: 62; Corticosteroids: 41;
Immunosuppressants: 9; None: 30
Smoker (IG1 / IG2): (28/71) vs. (36/71)
Number randomised (n = 142): 71 vs. 71
Number analysed (n = 138): ITT: (69/71) vs. (69/71); Per protocol: 50/71 vs. 61/71
Post-randomisation exclusion (n = 11): (6/71) vs. (5/71); Did not start the treatment:
3 (2 vs. 1); lost to follow-up:8 (4 vs. 4)
Interventions Group 1: Azathioprine administered at a dosage of 2 mg/kg/day
Group 2:Mesalamine was administered at a dosage of 3 g/day divided into 3 doses
All participants: treatment with aminosalicylates, metronidazole, and any other CD-
specific treatment had to be discontinued. Corticosteroids were allowed to be tapered
by standardized stepwise dose reductions within 6 weeks after surgery at the latest.
Symptomatic treatment with antacids, antidiarrhoeal agents, or spasmolytic agents was
allowed but had to be scrupulously recorded. Compliance with treatment was evaluated
by a simple questionnaire in which adverse events were also recorded. Patients receiving
AZA were regularly assessed by total blood cell count and serum transaminase values
to monitor any myelotoxicity and hepatotoxicity of the treatment. Patients were seen at
baseline and every 6 months
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Ardizzone 2004 (Continued)
Outcomes Duration of study: 24 months
1.Clinical relapsedefined as the presence of symptoms related toCD, variably associated
with radiologic, endoscopic, and laboratory findings, with a CDAI score >200, which
is considered severe enough to warrant treatment with a systemic corticosteroid at a
medium-high dose
2. Surgical Relapse defined as the presence of symptoms refractory tomedical treatment
or complications requiring another surgical procedure (e.g., occlusive disease, intra-
abdominal abscesses, or high-flow fistulas)
3. Adverse events
Notes Funding source: Not reported
Conflict of interest: Not reported
Sample size:Based on amaximum relapse rate at 2 years of 45%mesalamine, 62 patients
per treatment group was considered sufficient to detect a difference of ≥25% for the
AZA treatment group (type 1 error of 5%). The number of patients in each group was
increased to 68 to compensate for an anticipated drop out rate of 10%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After surgery, patients whomet the
inclusion criteria and who agreed to en-
ter the study were randomised to receive
mesalamine or AZA by a computer-gen-
erated list” and ”Randomization was per-
formed in blocks of 10”
Comment: computer generated block ran-
domisation
Allocation concealment (selection bias) Unclear risk Insufficient information tomake judgment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the study is open-label and
blinding is not performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to make judg-
ment, however it is unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotes: “In the intention-to-treat analy-
sis, all randomised patients who received at
least one dose of the study drug and were
subjected to the baseline evaluation were
considered for the analysis.”and “Outcome
measures were analysed in all randomised
patients who had taken at least one dose
of the study medication (intention-to-treat
population)…”
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Comment: withdrawals were low and bal-
anced across groups
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated in themethod sectionwere
assessed and reported
Other bias Low risk Quote: “No significant differences were ob-
served between the 2 treatment groups re-
garding age, sex, duration of disease, lo-
cation of disease, fistula and abscess at
surgery, surgical procedure, previous oper-
ations, and CD therapy during the previ-
ous 6 months”
Comment: baseline characteristics well bal-
anced across groups
Brignola 1995
Methods Study design: RCT, multicentre
Setting: Italy, 8 centres, 1990-1992 enrolment
Participants Inclusion: Patients with so-called curative resection, such as those who have undergone
removal of all macroscopic disease in the ileal or ileocaecal region
Exclusion: Patients with localization of CD in another region or having resection of
>100 cm were excluded
Age (IG1 / IG2) mean (SD): 36.5 ±14 overall; (39 ± 17) vs. (34 ± 10)
Sex (M:F): 42:45 overall; (22:22) vs. (20:23)
Type of surgery: Not reported
Previous surgery (IG1+IG2): 24 overall; (13/44) vs. (11/43)
Start of intervention after surgery: ≤ 1 month
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): 44 overall (22/44) vs. (22/43)
Number randomised (n = 87): 44/43
Number analysed (n = 85): (43/44) vs. (42/43)
Post-randomisation exclusion (n = 2): (1/44) vs. (1/43); Lost to follow up: 1 (1 vs 0);
protocol violation:1 (0 vs 1)
Interventions Group 1:Mesalamine tablets 3 g/day for 12 months (2 tablets Pentasa (500-mg) 3 times
a day)
Group 2: Identical placebo tablets
All participants: Laboratory tests performed at baseline after 1 month and then every
3 months for evaluation of hematologic, renal, and hepatic function
Outcomes Duration of study: 12 months
1. Clinical recurrence defined as worsening of the symptoms by at least 100 CDAI
points above the patient’s level at the previous visit and attainment of a CDAI score of
more than 150
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2. Endoscopic recurrence based on a standardised form for description of endoscopic
lesions by type (aphthous lesion, large ulcer, nodule, or narrowing) and characteristics
(number, size, and whether a diffuse or skip lesion
3. Severe endoscopic recurrences (i score of 3 and 4)
4.Withdrawal due to adverse events
Notes Funding source: Not reported
Conflict of interest: Not reported
Sample size: The severe endoscopic recurrence (score 3-4) rate in the placebo group
was estimated to be 50%. The decision was made to enrol 80 patients (40 per group)
to detect a significant difference in comparison with the active group (30% recurrence)
(one-tailed test; α level, 5%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Each center received material for
at least 4 cases labelled with a patient
code number according to a randomization
made in balanced blocks”
Comment: block random sequence gener-
ation, but method not described
Allocation concealment (selection bias) Unclear risk “Each center received material for at least
4 cases labelled with a patient code num-
ber according to a randomization made in
balanced blocks”
Comment: Unclear whether drug contain-
ers were identical.Insufficient information
to make judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The treatment blinding code was
broken in September 1993 when all the as-
sessments were finished; no serious adverse
event necessitated breaking of the code be-
forehand“
Comment: It is a double-blind trial, pa-
tients were receiving placebo tablets which
were identical to the study intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Endoscopists, unaware of the
treatment that the patient had received,
recorded on a standardized form a descrip-
tion of endoscopic lesions by type...At the
end of the trial, two investigators not pre-
viously involved in the patients’ follow-up
and unaware of which treatment the pa-
tients had received and also of the overall
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assessments provided by each center, inde-
pendently evaluated all of the standardized
forms with a description of endoscopic and
radiological responses; their assessments
were then compared with those furnished
by the investigators from the original cen-
ter...The treatment blinding code was bro-
ken in September 1993 when all the as-
sessments were finished; no serious adverse
event necessitated breaking of the code be-
forehand. “
Comment: blinding maintained till after
assessments were finished
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rateswere lowandbalanced across
groups with reasons reported
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated in the method section re-
ported
Other bias Low risk Quote: “Clinical characteristics that were
considered in our trial were well balanced
between the mesalamine group and the
placebo”
Comment: Groups well balanced at base-
line. No other apparent biases
Caprilli 1994
Methods Study design: RCT, multicentre,
Setting: Italy, 15 collaborating centres, 1990-1992 enrolment
Participants Inclusion: Age between 18 and 65 years for both sexes, disease limited to the terminal
ileum with or without involvement of caecum-ascending colon : resection had to be the
first one and judged to be ‘radical’ (complete removal of the macroscopically involved
intestinal segment) by the surgeon during operation: absence of skip lesions; diagnosis
of Crohn’s disease confirmed macroscopically and microscopically by standard criteria
Exclusion: Localization of the disease to the jejunum, proximal ileum, left colon or ano-
rectum: known side-effects from sulphasalazine or salicylates; severe diseases unrelated
to Crohn’s disease (for example, renal or liver dysfunction); treatment with drugs that
may alter intestinal pH (H,-receptor antagonists, omeprazole); pregnancy ; questionable
ability to co-operate and give consent
Age (IG1 / IG2) mean (range): 35.5 (16-61)) vs. 33.7 (16-58)
Sex (M:F): 55:40 overall; (32:15) vs. (23:25)
Type of surgery: Elective-71; Emergency-24
Previous surgery (IG1+IG2): Not reported
Start of intervention after surgery: ≤ 2 weeks
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Medication use (IG1+ IG2): Mesalazine-46; corticosteroids-59; cetronidazole-25; sul-
phasalazine-21
Smoker (IG1 / IG2): Not reported
Number randomised (n = 110): 55/55
Number analysed (n = 95): (47/55) vs. (48/55)
Post-randomisation exclusion (n = 17): (9/55) vs. (8/55); randomised, no endoscopy
at base: 15 (8 vs. 7); drop-out: 2 (1 vs. 1)
Interventions Group 1: 2.4 g/day of Eudragit-S coated mesalazine
Group 2: No treatment
All participants: Patients were seen for clinical and laboratory assessment at 2 weeks after
surgery, at 3, 6, and 12 months, and annually thereafter. Colon-ileoscopy was performed
at 6 and 12 months, and annually thereafter. Clinical, laboratory and endoscopic exam-
ination were brought forward if symptoms recurred. Patients requiring corticosteroids
or surgery were withdrawn from the study. Patients who stopped the treatment for more
than 2 weeks, or who presented with severe side-effects, were considered to be drop-outs.
Adverse events and reported compliance with the drug were recorded at each visit
Outcomes Duration of study: 24 months
1. Clinical relapse: Patients in whom CDAI was > 150, and who presented 100 points
over their previous value, were considered to be relapsed
2.Recurrence defined as the presence of typical endoscopic Crohn’s disease lesions in the
neoterminal ileum and/or anastomosis according to the criteria proposed by Rutgeerts
et al. (judged as no, mild or severe)
3. Adverse events (skin rash, epigastric pain, nausea, vomiting)
4.Withdrawal due to adverse events
Notes Funding source: Supported in part by Bracco SpA (Milan)
Conflict of interest: Not reported
Sample size: The study entailed the enrolment of 55 consecutive patients in each arm
of the trial, a number sufficient to demonstrate a fall in the recurrence rate from 90 to
80% with a power of 0.90 and a 0.05 one-sided type I error. Only the 95 patients with
almost 6 months of observation were considered in the statistical analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patientswere randomly al-
located to receive 2.4 g/day of Eudragit-
S coated mesalazine (Asacol, Bracco SPA,
Italy) or no treatment at all”
Comment: insufficient information on
random sequence generation
Allocation concealment (selection bias) Unclear risk Insufficient information to make judge-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This multicentre study was not
blind”
Comment: Study is open-label design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “On the first occasion, the endo-
scopist was unaware of the treatment; on
the second, the tapes were shown with
a different sequence and the endoscopist
was informed of treatment... The variabil-
ity sources of the recurrence classification
were evaluated...However, the results of the
reliability study suggest that lack of blind-
ness in the endoscopists collaborating on
the trial was no relevant. In fact, we found
that the endoscopists were not in disagree-
ment in the assessment of recurrence nor
was the diagnosis of recurrence affected by
endoscopists’ awareness of the kind of treat-
ment”
Comment: There was some form of blind
outcome assessment and the reliability
study comparing blind versus unblind as-
sessment showed that the lack of blinding
had no effect on outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The cumulative proportions of
symptomatic recurrence and asymptomatic
recurrence were estimated by the life ta-
ble method on the intention-to-treat prin-
ciple”
Comment: Attrition rate was low and bal-
anced across groups
Selective reporting (reporting bias) Low risk All outcome data stated in the method sec-
tion were reported
Other bias Low risk Quote: “the groups were homogenous for
age, duration of the disease, site and extent
of the lesions, clinical course perforating or
non-perforating), previous treatment, indi-
cation and type of surgery, and CDAI score
at operation.Malesmore common inMEZ
group”
Comment: groups well balanced at base-
line. No other apparent sources of bias de-
tected
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Methods Study design: RCT, multicentre,
Setting: Italy, 17 collaborating centres, Italy, enrolment 1997-2000
Participants Inclusion: Adults (18-65 years) with CD limited to the terminal ileum (lesions not
exceeding 1 m), with or without involvement of the caecum/ascending colon, evaluated
by colonoscopy and small bowel follow-through within 1 month before surgery; first
or second resection, and considered by the surgeon during the operation to be ‘radical’
(complete removal of the macroscopically involved intestinal segment); absence of skip
lesions; diagnosis of CD confirmed macroscopically and microscopically by standard
criteria
Exclusion: Localization of the disease to the jejunum, proximal ileum, transverse colon,
left colon or ano-rectum; small bowel resection exceeding 1 m; known side-effects from
sulphasalazine or salicylates; severe diseases unrelated toCrohn’s disease (e.g. renal or liver
dysfunction); treatmentwith drugs likely to affect intestinal pH ; pregnancy; questionable
ability to co-operate; inability to give informed consent
Age (IG1 / IG2) mean: 33.8 vs 36.4; overall age not reported
Sex (M:F): 114:93 overall; (49:52) vs (64/41)
Type of surgery: Emergency: 45; Elective: 161
Previous surgery (IG1+IG2): First- 166; second-40
Start of intervention after surgery: ≤ 2 weeks
Medication use (IG1+ IG2):Mesalamine-153; Steroids-123; Antibiotics-71; Immuno-
suppressants-20
Smoker (IG1 / IG2): (21/ 101) vs (27/105)
Number randomised (n = 206): 101/105
Number analysed (n = 206): (99/101) vs (103/105)
Post-randomisation exclusion (n = 61): (23/101) vs (38/105); Withdrawals from clin-
ical control -20 (6 vs 14); withdrawals from endoscopy -41 (17 vs. 24)
Interventions Group 1: 4.0 g/day of oral Eudragit-S-coated mesalazine (Asacol). Patients received five
tablets of mesalazine (800 mg) divided into three doses (1 + 2 + 2 tablets)
Group 2: 2.4 g/day of oral Eudragit-S-coatedmesalazine (Asacol). Patients received three
tablets of mesalazine (800 mg) divided into three doses (1 + 1 + 1 tablets) plus two tablets
of placebo identical in appearance
All participants: No other pharmacological treatment was given, with the exception of
anti-diarrhoeal drugs on demand. Patients were seen for clinical and laboratory assess-
ment 2weeks after surgery, and then at 6 and 12months. Colon ileoscopy was performed
at 12 months. Clinical, laboratory and endoscopic examinations were brought forward if
the recurrence of symptoms was reported before the scheduled follow-up. Adverse events
and reported compliance with the drug were recorded at each visit
Outcomes Duration of study: 12 months
1. Endoscopic recurrence defined as the presence of typical endoscopic CD lesions in
the neoterminal ileum and/or anastomosis, and was graded according to the criteria of
Rutgeerts et al. Three different degrees of endoscopic recurrence were evaluated: (i) an
endoscopic score of > 0; (ii) an endoscopic score of > 1; and (iii) an endoscopic score of
> 2 (severe recurrence)
2. Clinical recurrence defined as CDAI > 150 points or an increase in CDAI score of
> 100 points
3. Adverse events
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4.Withdrawals due to adverse events
Notes Funding source: supported by a grant from Giuliani SpA, Milan, Italy
Conflict of interest: Not reported
Sample size: Assuming that mesalazine, 2.4 g/day, would reduce severe endoscopic
recurrence from 70% to 55% at 1 year of follow-up, it was hypothesized that mesalazine,
4.0 g/day, would reduce the rate of severe endoscopic recurrence to 30%. The number
of patients needed to ensure a type 1 and type 2 error level of 5% calculated was 85
patients per group plus 25% drop-outs (i.e. a further 43 patients). Therefore, the total
number of patients required was 213
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomized in
blocks of four according to a computer-
generated randomization scheme provided
by an independent institution at the begin-
ning of the trial and forwarded to the De-
partment of Clinical Trials at Giuliani SpA.
”
Comment: computer-generated randomi-
sation
Allocation concealment (selection bias) Low risk Quote: “...provided by an independent in-
stitution at the beginning of the trial and
forwarded to the Department of Clinical
Trials at Giuliani SpA”
Comment: Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “All patients and investigators were
blind with regard to treatment allocation”
Comment: double-blinded RCT, but no
explanation how were the conditions of
blinding achieved. Given the variation in
doses between study groups (5 vs. 3 tablets)
, blinding is unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”The treatment blinding code was
broken in June 2000 when all assessments
had been completed”
Comment: assessors were blinded to treat-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Outcome measures were analysed
in all randomized patients who had taken
at least one dose of the study medication
(intention-to-treat population)”
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Comment: Attrition rates were similarly
low and balanced across groups except for
the endoscopy outcome where attrition
rates were about 20%
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated at the method section re-
ported adequately
Other bias Low risk Groups well balanced at baseline, compli-
ance satisfactory; no other apparent sources
of bias detected
Ewe 1989
Methods Study design: RCT, multicentre
Setting: Germany / 16 surgical and medical centres; study period not reported
Participants Inclusion: Adult patients resected for CD by one of the medical centres; resection had
to be curative with no macroscopically inflamed intestine left; diagnosis of CD had to
be confirmed macro and microscopically
Exclusion: Patients not resected according to the standard policy of the individual (rad-
ical or non-radical); inability/refusal to give written consent; questionable ability to co-
operate; age less than 18
Age (IG1 / IG2) median (range): 31 (15-66) overall; 32 (16-66) vs 30 (15-62)
Sex (M:F): 113:119 overall; (48:63) vs (65:56)
Type of surgery: Not reported
Previous surgery (IG1+IG2): 94 (48/46)
Start of intervention after surgery: Immediately postoperatively
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): Not reported
Number randomised (n = 232): 111/121
Number analysed (n = 206): (101/101) vs (105/105)
Post-randomisation exclusion (n = 88): (47/111) vs (41/121); Noncoop-57 (31 vs 26)
; technical-18 (8 vs 10); medical-13 (8 vs 5)
Interventions Group 1: Sulfasalazine 3 g daily for 3 years
Group 2: Similar placebo (size, colour, form)
All participants:Medication initiated while in hospital. Control visits at 3 months and
every 6 months thereafter. Colonoscopy not obligatory, although encouraged
Outcomes Duration of study: 3 years
1. Recurrence of CD proven by radiology, endoscopy or operation (>3 months, >1 year,
>2 years, 3 years)
Notes Funding source: supported by Deutsche Forschungsgemeinschaft grant Ew 4/12,14,
16/1-3
Conflict of interest: Not reported
Power calculation: Not reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Yes, we carried out random allo-
cation. We got the key from our statistical
department”
Comment: Whilst the medical treatment
part of the study is reported as randomised
and double blind, there was no further in-
formation on this in the trial. However,
based on correspondence on the 11/10/
2018 with the lead author (Professor Ewe)
, the review authors conclude that random
allocation was probably done
Allocation concealment (selection bias) Unclear risk Insufficient information tomake judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medical treatment part of the study is re-
ported as randomised and double blind.
Dummy tablet similar to SZ has been used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote “Yes, the people who assessed the
outcomes were aware of the intervention
patients were allocated to”
Comment: Confirmed via correspondence
on the 11/10/2018 with the lead author
(Professor Ewe)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall attrition rate was around 37%,
however, compared to the event risk (60%)
, it was not sufficient to introduce bias
Selective reporting (reporting bias) High risk Trial registration is not available and ad-
verse events outcome was not reported
Other bias Low risk Baseline characteristics appear to be bal-
anced across groups
Florent 1996
Methods Study design: RCT, multicentre
Setting: France and Belgium;12 medical centres; 1989-1991
Participants Inclusion: All patients treated by ’curative’ resection for CD and whose anastomosis was
within the reach of colonoscopy were eligible for the study. Crohn’s disease diagnosis was
established by the convergence of clinical, radiological, endoscopic and histological data
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Exclusion: Pregnant or breastfeeding women, women of childbearing potential not re-
ceiving effective contraception, patients with a permanent stoma, subjects having un-
dergone a small intestinal resection of more than 100 cm prior to the pretrial operation,
and patients having a history of peptic ulcer, a known hypersensitivity to salicylates or a
significant renal, hepatic or haematological disorder
Age (IG1 / IG2) mean (SD): 33.5±12 overall; 35±13 vs 32±11; overall age not reported
Sex (M:F): 56:70 overall; (23:42) vs (33:28)
Type of surgery: Emergency: 45; Elective: 161
Previous surgery (IG1+IG2): First- 166; second-40
Start of intervention after surgery: ≤ 15 days
Medication use (IG1+ IG2):Mesalamine-153; Steroids-123; Antibiotics-71; Immuno-
suppressants-20
Smoker (IG1 / IG2): (17/ 65) vs (22/61)
Number randomised (n = 126): 65/61
Number analysed (n = 106): (55/65) vs (51/61)
Post-randomisation exclusion (n = 14): (8/65) vs (6/61); Lost to follow-up -5 (0 vs 5)
; Intercurrent pathology-2 (1 vs 1); Protocol violation-3 (2 vs 1); Error of inclusion-1 (0
vs 1); Colonoscopy failure/refusal-3 (0 vs 3)
Interventions Group 1: Claversal, two 500 mg tablets three times daily
Group 2: Placebo, two 500 mg tablets three times daily
All participants: Metronidazole and antibiotics were allowed within the perioperative
period. Sulfasalazine, corticosteroids (except for substitutive doses of hydrocortisone in
patients with post-steroid adrenal insufficiency) and immunosuppressive agents were not
allowed during the trial
Outcomes Duration of study: 12 weeks
1.Endoscopic recurrence defined as the presence of ulcerative lesions at the anastomotic
level (aphthous, superficial or deep) owing to its poor reproducibility, classified according
to Rutgeerts et al. (i ≥ 1)
2. CDAI score
Notes Funding source: Supported by a grant from SmithKline Beecham Laboratories
Conflict of interest: Not reported
Power calculation:An assumption was made that 80% of participants on placebo would
have an endoscopic relapse. A reduction of 30% in the relapse rate in the Claversal group
was considered as the minimal clinical significant decrease. The number of patients
requiredwas 50per arm. Estimating that 20%of patients would prove to be non evaluable
a total of 126 patients were randomised
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote:”Randomization was carried out us-
ing a permutation table within each centre“
Comment: Patients were classified into
three categories and it seems stratified
randomisation using permuted blocks has
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been used. However no further details pro-
vided
Allocation concealment (selection bias) Unclear risk Quote: ”The treatment was started as soon
as feeding was resumed, and no later than
the 15th postoperative day, andwas admin-
istered blindly over 12 weeks
Comment: Insufficient information to
make judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The treatment was started as soon
as feeding was resumed, and no later than
the 15th postoperative day, andwas admin-
istered blindly over 12 weeks.”
Comment: Study is placebo controlled,
but no information regarding the placebo
tablet provided and whether interventions
were sufficiently identical to ensure blind-
ing of personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information tomake judgment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rates and reasons for attrition were bal-
anced across groups
Selective reporting (reporting bias) High risk Data on CDAI reported as means ±SD.
Clinical relapse CDAI≥200 as one of rea-
sons for withdrawal not reported, although
it should have been as CDAI was assessed
at 12 weeks
Other bias Low risk Groups balanced at baseline, except for
ESR which was significantly higher in the
MES group. The authors did not consider
this sufficient to introduce bias. No other
apparent sources of bias detected
Hanauer 2004
Methods Study design: RCT, multicentre
Setting: USA and Belgium / 5 centres; 1992 - 1996
Participants Inclusion: Patients 18 and 65 years of age, with diagnosis of CD for at least 6 months
and scheduled for curative ileo-caecal resection; ability to start oral nutrition within 7
days of operation, need for curative ileo-caecal resection, and resection margins free of
inflammation
Exclusion:Active perianal disease or any active disease in other segments of the intestine,
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anti-TNF , and/or investigational treatment within 4 months prior to surgery; current
treatment with 5-ASA, azathioprine/6MP, or methotrexate; bowel surgery performed
less than 3 months previously; history of colostomy or ileostomy; infections, neoplasia,
or uncontrolled diseases; or anticipation of noncompliance with protocols. Subjects who
were receiving steroids preoperatively were tapered and weaned according to a strict
schedule
Age (IG1 / IG2) mean (SD): 34.4 ±11.0 overall; 34.9 ±11.5 vs 34.1 ±10.9 vs 34.2 ±10.
9
Sex (M:F): 60:71 overall; (23:24) vs (19:25) vs (18:22)
Type of surgery: Not reported
Previous surgery (IG1+IG2): 18 (7/11)
Start of intervention after surgery: Therapy initiated before postoperative hospital
discharge
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): Not reported
Number randomised (n = 131): 47/44/40
Number analysed (n = 131): (47/131) vs (44/131) vs (40/131)
Post-randomisation exclusion (n = 27): (12/47) vs (7/44) vs (8/40);Withdrew consent
-5 (1 vs 2 vs 2); Surgical complication -3 (2 vs 0 vs 1); Noncompliance-9 (2 vs 4 vs 3);
Lost to follow-up -10 (4 vs 2 vs 4)
Interventions Group 1: 50 mg of 6-mercaptopurine (Purinethol) once daily
Group 2: 3 g of Mesalamine (Pentasa); 4 capsules of 250mg, 3 times daily
Group 3: Identical matching placebo
All participants: Presurgical therapy, including aminosalicylates, antibiotics, or im-
munomodulators, was discontinued before surgical resection and was not allowed during
the postoperative trial. Preoperative treatment with corticosteroids was completely ta-
pered by 3 months after hospital discharge at a rate determined by the treating physician.
No concurrent treatment for Crohn’s disease, aside from topical therapy for perianal
disease, was allowed during the duration of the trial. Continuous use of nonsteroidal
anti-inflammatory drugs was not allowed during the study. If the white blood cell count
and platelet counts fell below 4500/L or 150,000/L, respectively, the dosage of 6-MP
was reduced by one half
Outcomes Duration of study: 24 months
1. Endoscopic recurrence defined as i ≥ 1 according to the Rutgeerts scoring system:
i1-i2 mild to moderate; i3-i4 severe. Relapse defined as i ≥1
2. Clinical recurrence defined as CDAI > 150 points or an increase in CDAI score of
> 70 points or higher from baseline
3. Histological score assessed by the Geboes scoring system
4. Adverse events
5. Serious adverse events
6. Withdrawal due to adverse events
Notes Funding source: Not reported; However, authors contacted by email on 02/08/2018
and declared none
Conflict of interest:Not reported; However, authors contacted by email on 02/08/2018
stating that study was funded by Crohn’s and Colitis Foundation
Power calculation: Sample size calculations were performed for the endoscopic criteria,
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using 2-sided of 0.05 and 80% power, based on a predicted endoscopic recurrence of
75% at 1 year in the placebo group. A sample size of 50 in each group allows sufficient
power to detect a 40% reduction in mild Crohn’s disease lesions and a 75% reduction
in more severe lesions at 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotes: Patientswere randomized by a cen-
tral computer by permuted blocks of 6 (un-
known to investigators) per center to re-
ceive mesalamine (Pentasa; Marion Mer-
rill Dow, Kansas City, MO) 3 g daily, 6-
MP (Purinethol; BurroughsWellcome, Re-
search Triangle Park, NC) 50 mg daily, or
placebo
Comment: Computer generated random
sequence
Allocation concealment (selection bias) Low risk Quotes: “Medications were prepared and
dispensed by an assignedpharmacist at each
site’s investigational pharmacy whowas not
directly involved in the care of the patients”
Comment: Treatment controlled by phar-
macies at each centre
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotes: “Medications were prepared and
dispensed by an assignedpharmacist at each
site’s investigational pharmacy whowas not
directly involved in the care of the patients”
and “An evaluating (treating) physician fol-
lowed up each patient and was blinded as
to the study drug and laboratory results”
Comment: Placebo-controlled, double-
blind RCT. However, it is unclear whether
both study drugs were sufficiently identical
with the placebo to blind study participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “Patient evaluation consisted of as-
sessments of clinical, endoscopic, and ra-
diographic disease activity at each study site
by the blinded physician” and “Colono-
scopic examinations with endoscopic de-
scriptions and photography of the anas-
tomosis and pre-anastomotic ileum were
performed by the blinded investigators
(all gastroenterologists) at months 6, 12,
and 24“ and “Radiographic interpretations
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were performed by the blinded inflamma-
tory bowel disease radiologist at each insti-
tution”
Comment:Assessors blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotes: “The clinical recurrence rates were
determined using ITT”
Comment: ITT analysis applied, attrition
low, similar and balanced across groups
Selective reporting (reporting bias) Low risk Comment: All outcomes stated in the
method section reported
Other bias Low risk Quote: ”There were no statistical differ-
ences in patient age, sex, disease duration,
indications for surgical resection, or preop-
erative disease activity among the 3 groups”
Comment: Groups well balanced at base-
line. No other apparent sources of bias de-
tected
Herfarth 2006
Methods Study design: Multicentre RCT
Setting: Not stated (multicentre RCT)
Participants Inclusion: People with Crohn’s who had undergone resective surgery
Exclusion: Homozygous TPMT
Age: Not reported
Sex: Not reported
Type of surgery: Not reported
Previous surgery: Not reported
Start of intervention after surgery: within 2 weeks postoperative
Medication use (IG1+ IG2):
Smoker (IG1 / IG2): Not reported
Number randomised (n = 79): 42/37
Number analysed (n = 37): 18/19
Post-randomisation exclusion (n = 42)
Interventions Group 1: 2.0 to 2.5 mg/g body weight/day azathioprine
Group 2: 5-ASA 4 g/day
All participants: Not stated
Outcomes Duration of study: 1 year (study was discontinued after one year)
1. Treatment failure (due to severe endoscopic recurrence, lack of efficacy and AE related
to study drug)
2. Clinical or severe endoscopic relapse
3. Severe endoscopic relapse
4. Clinical relapse (reviewer calculated: clinical or severe endoscopic relapse minus severe
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endoscopic relapse)
5. Adverse events
6. Withdrawal due to adverse events
Notes Funding source: Dr. Falk Pharma GmbH, Freiburg, Germany
Conflict of interest: Not reported
Power calculation: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients in the present study were assigned
to one of the two treatment groups (5-ASA
or azathioprine) at random
For creation of the randomisation list the
programme ”Rancode +“ (version 3.6) of
IDV, Gauting (Germany) was used. The
randomisation into two treatment groups
was performed in blocks of four. After
voluntary written informed consent was
obtained and basic selection criteria were
checked, the investigator requested the al-
location of a unique patient code number
(randomisation number, consecutively al-
located to each patient), and received med-
ication packs with the randomisation num-
ber for the patient”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Allocation concealment (selection bias) Low risk “The randomization code was prepared
and stored by a statistician from a CRO,
whowas not involved in the conduct nor in
the analysis of the study. TheQualified Per-
son of the Sponsor and the contract manu-
facturer responsible for the preparation of
the double-dummy patients sets received a
copy of the randomization list, which was
safely stored at both sites, without allowing
access by other people. Neither the investi-
gator nor the study team from the clinical
operation from the sponsor nor the CRO
had access to the random list”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Blinding of participants and personnel
(performance bias)
Low risk “This was a double-blind, double-dummy
study. Patients randomized to administer
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All outcomes 5-ASA had to take 5-ASA VERUM tablets
AND azathioprine PLACEBO tablets. Pa-
tients randomized to receive azathioprine
had to administer azathioprine VERUM
tablets AND 5-ASA PLACEBO tablets
Therefore, neither the investigator, nor the
patients, nor the sponsor were ware of the
TXapatient received until the databasewas
clean, closed, and the code was broken”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “This was a double-blind, double-dummy
study. Patients randomized to administer
5-ASA had to take 5-ASA VERUM tablets
AND azathioprine PLACEBO tablets. Pa-
tients randomized to receive azathioprine
had to administer azathioprine VERUM
tablets AND 5-ASA PLACEBO tablets
Therefore, neither the investigator, nor the
patients, nor the sponsor were ware of the
TXapatient received until the databasewas
clean, closed, and the code was broken”
Comment: Confirmed by correspondence
from Muller R (2/5/2012)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “The study was stopped prema-
turely after an interim-analysis due to a
high therapy failure rate. 38 patients (AZA
18 pat.; 5-ASA 20 pat.) completed the
study and could be evaluated regarding
the primary endpoint therapy failure. The
other pat. terminated the trial prematurely
due to the study stop, but were also eval-
uated for adverse events (AE) and adverse
drug reactions (ADR)”
Comment: 51% of randomised partici-
pants discontinued. High risk for primary
outcome and low risk for AE and with-
drawal due to AE
Selective reporting (reporting bias) Unclear risk Insufficient information as trial registration
was not available and study was published
as abstract
Other bias Unclear risk Insufficient information as study was pub-
lished as abstract
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Methods Study design: RCT, multicentre
Setting: Austria, Denmark, Germany, Norway, Sweden, and Switzerland, 29 university/
teaching hospitals; 1992-1996
Participants Inclusion: Adults (18-70 years) who underwent a resective surgical procedure (radical
or nonradical) for a CD-specific lesion at 1 of the participating centers;
diagnosis of CD established by generally accepted endoscopic, histological, and/or ra-
diological criteria at least 6 months before surgery; evaluation of disease location by a
complete investigation of the gastrointestinal tract (gastroscopy, colonoscopy, and small
bowel radiography) within a maximum of 1 year before the index surgery; and ability to
start oral nutrition (and, thus, oral medication) within the first 10 postoperative days
Exclusion: Exclusion criteria included contraindications for use of mesalamine; preg-
nancy or intention of pregnancy within the next 18 months; nursing; short bowel syn-
drome; clinically significant lactase deficiency; any severe additional disease; diagnosis of
primary sclerosing cholangitis; presence of an ileocolonic stoma; more than 3 surgeries
preceding the index surgery; and failure to obtain informed consent
Age (IG1 / IG2) mean (SD): 33.6 ± 10.1 overall; 33.5 ± 10.0 vs 33.8 ± 10.2
Sex (M:F): 156:162 overall; (71:81) vs (85:81)
Type of surgery: radical - 244 (121/123); nonradical-75 (35/40)
Previous surgery (IG1+IG2): 18 (7/11)
Start of intervention after surgery: ≤ 10 days
Medication use (IG1+ IG2): Sulfasalazine- 190 (96/94); Metronidazole -32 (10/22);
Immunosuppressants-18 (8/10);Corticosteroids-187 (86/101); TPN-35 (16/19)
Smoker (IG1 / IG2): not reported
Number randomised (n = 324): 154/170
Number analysed (n = 318): (152/154) vs (166/170)
Post-randomisation exclusion (n = 20): (7/154 ) vs (13/170); Lost to follow-up-14 (5
vs 9); did not start treatment-6 (2 vs 4)
Interventions Group 1: 4 g mesalamine (Pentasa) per day divided into 3 doses (1.5, 1, and 1.5 g) or
placebo. One tablet of Pentasa contains 500 mg encapsulated in ethylcellulose micro-
granules and pressed to form a tablet with microcrystalline cellulose
Group 2: Placebo tablets of identical appearance and consistency containing additional
microcrystalline cellulose to compensate for the mesalamine microgranules
All participants: Corticosteroids were allowed to be tapered by standardized stepwise
dose reductions within 6 weeks. Concomitant medication such as glucocorticoids with
the exception of initial tapering, nonsteroidal anti-inflammatory drugs, immunosuppres-
sive drugs, metronidazole, methotrexate, sulphasalazine, and other 5-aminosalicylates
were not allowed. Symptomatic treatment with antidiarrhoeal, antacid, or spasmolytic
medication was allowed but had to be thoroughly documented for calculation of the
CDAI. Similarly, patients were requested to report precisely any other concomitant med-
ication in their diary. Patients were supplied with study medication for the subsequent
3 months at each follow-up visit. Any tablets not used had to be returned. Mesalamine
and acetylmesalamine were determined in blood samples drawn at each visit. Patients
were considered noncompliant if medication was interrupted for a total of >10% of
their individual trial course. Endoscopic evaluation of the colon and, if possible, of the
anastomosis was recommended at 6 weeks and 18 months after surgery or at the time of
clinical relapse
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Outcomes Duration of study: 18 months
1. Endoscopic recurrence defined as i ≥ 1 defined by Rutgeerts et al
2. Clinical recurrence defined by 1 of the following: increase in CDAI above 250;
increase inCDAI above 200 but by aminimum of 60 points over the lowest postoperative
value for 2 consecutive weeks, indication for surgery; development of a new fistula; and
occurrence of a septic complication
3. Adverse events
4. Withdralwal due to adverse events
Notes Funding source: not reported
Conflict of interest: Not reported
Power calculation: Based on a maximum relapse rate with placebo of 50% and an
absolute effect size of 15%with the active drug, a sample size of 150patients per treatment
group was calculated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated randomiza-
tion scheme was provided by the Insti-
tut fur Medizinische Dokumentation und
Statistik at the University of Koln at the
beginning of the trial and forwarded to
theDepartment of Galenics at Ferring A/S,
Denmark. Randomization was performed
in blocks of 10 for each of the participating
centers”
Comment: Computer generated random
sequence
Allocation concealment (selection bias) Unclear risk Quote: “ “In addition, each center retained
sealed opaque envelopes containing patient
numbers and treatment allocations, which
were only allowed to be opened in case of a
serious adverse event that necessitated dis-
closure of the type of treatment”
Comment: Unclear whether envelops were
sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Placebo tablets of identical ap-
pearance and consistency contained addi-
tional microcrystalline cellulose to com-
pensate for themesalaminemicrogranules..
. All patients and investigators were blinded
regarding treatment allocation”
Comment: Placebo blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Randomization was performed in
blocks of 10 for each of the participating
centers. This information was kept confi-
dential at the Department of Quality As-
sessment at Ferring and the statistical cen-
ter in Cologne and was only available to the
Department of Galenics [...] An Endpoint
Committee consisting of 2physicians and1
surgeon, not participating in the trial,made
a final decision about questionable cases of
protocol violations and relapses”
Comment: Probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotes: “Outcomemeasures were analyzed
in all randomized patients who had taken at
least 1 dose of studymedication (intention-
to-treat population)”
Comment: Attrition rates and reasons were
balanced across groups
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated in the method section re-
ported
Other bias Low risk Quote: ”No significant differences were de-
tected between the 2 treatment groups for
any of the parameters investigated”
Comment: Groups well balanced at base-
line. No additional sources of bias detected
McLeod 1995
Methods Study design: RCT, multicentre
Setting: Canada; 1986-1993
Participants Inclusion: All patients who had undergone a surgical resection for Crohn’s disease at
one of the participating hospitals and who had no gross residual disease were eligible for
entry provided they were randomized within 8 weeks of the date of surgery
Exclusion: Patients with residual Crohn’s disease (including gastroduodenal Crohn’s
disease) with the exception of asymptomatic anal skin tags or anal stenosis; abnormal
renal function with a serum creatinine level >130 µmol/dL or 1.5 mg/dL; if they were
taking prednisone, sulphasalazine, metronidazole, or imuran and these drugs could not
be discontinued
Age (IG1 / IG2) mean (SD): 38.0 ± 13.1 overall; 38.9 ± 13.1 vs 38.9 ± 13.2
Sex (M:F): 98:65 overall; (49:38) vs (49:27)
Type of surgery: Small bowel resection-15( 8/7); Terminal ileal/ileocolic resection-109
(59/ 50); Segmental colon resection- 7 (7/0); Total abdominal colectomy-3 (1/2); Proc-
tocolectomy-25 (13/12);Proctectomy-10 (3/7)
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Previous surgery (IG1+IG2): 179 surgical resections performed in the 163 patients
Start of intervention after surgery: ≤ 8 week
Medication use (IG1+ IG2): not reported
Smoker (IG1 / IG2): not reported
Number randomised (n = 169): 88/81
Number analysed (n = 163): (87/88) vs (76/81)
Post-randomisation exclusion (n = 21): (8/88) vs (13/81); Randomised but did not give
consent-6 (1 vs 5); refused follow-up because of personal reason-11; death of multiple
myeloma-1;moved toEurope - 1; bowel resection (suspectedCrohn’s disease, but resected
specimen was pathologically normal) -2 [reasons not reported separately]
Interventions Group 1: 3 g/ day of mesalamine taken as six 250-mg tablets twice daily
Group 2: six identical-looking placebo tablets twice daily
All participants: Study medication was mailed to the patient every 3 months. At 3-
month intervals, all patients were interviewed by telephone by a research nurse to deter-
mine their clinical status, ensure they were not taking any other prescribed medications,
and assess their compliance. At yearly intervals, all subjects were assessed by an investi-
gator and appropriate radiological or endoscopic investigations performed. If endoscopy
could not be performed, then an air contrast barium enema or ileostomy injection was
performed. Once patients were judged to have symptoms caused by Crohn’s disease that
required treatment and there was radiographic or endoscopic confirmation of disease,
they were considered a failure. Further treatment was at the discretion of their attending
physician or surgeon. Compliance was determined by questioning the subjects and by
pill counts of all medication returned at the annual visit
Outcomes Duration of study: follow-up period 72 months max
1. Symptomatic Recurrence defined as symptoms compatible with Crohn’s disease
that were severe enough to warrant treatment in the opinion of the investigator plus
radiological or endoscopic evidence of disease using the criteria outlined criteria (at least
one of the following features had to be present to make the diagnosis of recurrent disease:
aphthous ulcers; longitudinal or punched out ulcers; cobblestoning or nodularity of
the bowel; stricture of the bowel associated with edema, ulceration, or erythema of the
mucosa; pseudopolyps; or mucosal bridging)
2. Endoscopic and radiologic relapse rate defined as the presence of endoscopic or
radiological evidence of disease and included both asymptomatic and symptomatic pa-
tients. At least one of the following features had to be present to make the diagnosis of
recurrent disease: aphthous ulcers; longitudinal or punched out ulcers; cobblestoning
or nodularity of the bowel; stricture of the bowel associated with edema, ulceration, or
erythema of the mucosa; pseudopolyps; or mucosal bridging. a septic complication
3. Adverse events
4. Withdrawal due to adverse events
Notes Funding source: Not reported
Conflict of interest: Not reported
Power calculation: Based on a review of retrospective studies in the literature, it was
estimated that the symptomatic recurrence rate in the control group would be 12.5%
per year. Using a sample size calculation based on survival analysis for two independent
groups with censoring, it was estimated that 178 patients would have to be accrued
during a period of 3 years and followed up for a maximum of 6 years to detect a 50%
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decrease in recurrence (6.25% per year) in the treatment group with a one-tail 06 of 0.
05 and power of 0.80
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”“The randomization scheme
was computer generated by the Clini-
cal Research Support Unit, University of
Toronto, and maintained by the pharma-
cies at the Toronto Hospital, General Divi-
sion, and St. Mary’s Hospital, Rochester”
Comment: Computer generated random
sequence
Allocation concealment (selection bias) Low risk Quote:“All investigators and patients were
blinded with respect to treatment alloca-
tion”
Comment: No further details provided,
however, author contacted 27 November
2009 and confirmed that central allocation
was used
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote:“Subjects in the control group took
six identical-looking placebo tablets twice
daily”
Comment:Patients and investigators were
blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote:“All patient records were reviewed
by an adjudication committee of five inves-
tigators (R.S.M., B.G.W., A.H.S., P.W.C.,
and K.O.) blinded to patient treatment al-
location.” And “The charts of patients who
were noncompliant were reviewed by two
blinded gastroenterologists (A.H.S. and P.
W.C.), who determined whether noncom-
pliance was secondary to adverse effects po-
tentially related to the medication”
Comment:Blinding of assessors performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were low and reasons for
withdrawal were balanced across groups
Selective reporting (reporting bias) Low risk Trial registration not available, however,
all outcomes stated in method section re-
ported
60Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McLeod 1995 (Continued)
Other bias Low risk Quote: “The characteristics of the two
groups, which are listed in Table 1, were
similar”
Comment:Groups balanced at baseline.
No other apparent sources of bias detected
Reinisch 2010
Methods Study design: RCT, multicentre
Setting: Austria, the Czech Republic, Germany and Israel ; 21 centers, 2002-2007
Participants Inclusion:Male or female patients aged 18-70 years with a diagnosis of CD confirmed by
endoscopy and histology were eligible for screening if they had (1) undergone resection of
the terminal ileum and partial colectomy with ileocolonic resection for complications of
ileal CD with construction of an ileocolonic anastomosis in the preceding 6-24 months;
(2) not experienced clinical recurrence due to CD since resection; and (3) a Crohn’s
disease activity index (CDAI) score <200 in the preceding 1-2 weeks. Patients with
moderate endoscopic recurrence (Rutgeerts grade i2a: >5 aphthous lesions with normal
mucosa between the lesions, or skip areas of larger lesions) or severe endoscopic recurrence
(i3-i4: diffuse aphthous ileitis with diffusely inflamed mucosa, or diffuse inflammation
with larger ulcers, nodules and/or narrowing) were recruited into the study
Exclusion: Patients with a short bowel syndrome, an ileocolonic stoma, a thiopurine
methyltransferase genotype, patients who had received treatment with immunosuppres-
sant agents (methotrexate, ciclosporin, 6-MP, azathioprine or 6-thioguanine (6-TG) or
anti-tumour necrosis factor a (TFNa) since resection, corticosteroids or oral antibiotics
(e.g. metronidazole or ciprofloxacin) for >4 weeks since resection, non-steroidal anti-
inflammatory drugs (NSAIDs) within the preceding 2 weeks (other than paracetamol
or low-dose acetylsalicylic acid); patients who currently had strictureplasty (unless the
present stricture plasty macroscopically showed no inflammation at the time of the index
operation) or had serum creatinine >130 µmol/l. Patients were excluded if endoscopy
revealed no lesions (grade i0), <5 aphthous lesions (grade i1) and/or if lesions were con-
fined to the ileocolonic anastomosis (i.e. <1 cm long) (grade i2b). Patients in the latter
category (grade i2b) were excluded since this presentation is associated with a lower risk
of clinical recurrence
Age (IG1 / IG2) mean: 35.8 ± 12.08 overall; 35.5 ± 13.6 vs 36.0 ± 10.7
Sex (M:F): 44: 34 overall; (24:17) vs (20/17)
Type of surgery: Not reported
Previous surgery (IG1+IG2): 1 or 2 surgeries-114 (63/51)); >2 surgeries -12 (4/8)
Start of intervention after surgery: 6-24 months
Medication use (IG1+ IG2): Mesalazine - 54 (28/26); Sulfasalazine- 5 (4/1); Budes-
onide- 22 (9/13); Corticosteroids- 39 (23/16); Azathioprine- 14 (6/8); Infliximab-3 (2/
1); Other - 12 (6/6)
Smoker (IG1 / IG2): 37 (17/20)
Number randomised (n = 78): 41/37
Number analysed (n = 78): (41/41) vs (37/37)
Post-randomisation exclusion (n = 9): (4/41) vs (5/37) ; Lack of cooperation-7 (4 vs
3); lack of efficacy-2 (0 vs 2)
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Interventions Group 1:Azathioprine 2.0 - 2.5mg/kg/day (Azafalk 50 mg tablets) + placebomesalazine
tablets
Group 2: Mesalazine 4 g/ day (Eudragit L-coated 500 mg tablets (Salofalk)) + placebo
azathioprine tablets
All participants: Medications prohibited during the study: immunosuppressants other
than study drug, allopurinol, oxipurinol or thiopurinol, azathioprine-containing or
mesalazine containing drugs other than study drug, anti-TNFa therapy, oral antibiotics
for >4 weeks or more than three cycles of 2 weeks, NSAIDs for >2 weeks, corticosteroids
and cimetidine
Outcomes Duration of study: 52 weeks
1. Therapeutic failure (Clinical relapse) defined as CDAI score ≥200 and an increase
of ≥60 points from baseline or study drug discontinuation due to lack of efficacy or an
intolerable adverse drug reaction
2. Endoscopic recurrence defined by endoscopic Rutgeerts score ≥i2 only (endoscopic
recurrence data were excluded from the analysis as the inclusion criteria suggest that
people with moderate to severe endoscopic relapse were included)
3. Health-related quality of life based on IBDQ score at 12 months
4. Adverse events
5. Clinical recurrence follow-up defined as a Rutgeerts score between i2-i4 within 24
months after the 1-year treatment
Notes Funding source: Dr Falk Pharma GmbH, Freiburg, Germany
Conflict of interest: WR has received an unrestricted grant from Dr. Falk Pharma. EFS
and KRH have received speaker’s honoraria. KD, RG and RM are employees of Dr.
Falk Pharma. SA, WP, OS, ML, SB-M, AT, ES and MS have no conflicts of interest
to declare. In part, AT, ES and MS are supported by the Robert Bosch Foundation,
Stuttgart, Germany
Power calculation: The sample size calculation for the primary end point estimated that
62 evaluable patients (31 per treatment arm) were needed to have 80% power to detect a
difference of 35% in favour of azathioprine versus mesalazine for the reduction in the 1
year therapeutic failure rate (one-sided α = 0.025). To allow for non-evaluable patients,
a population size of 76 patients (38 per treatment arm) was planned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “..a central randomisation was per-
formed via five computer-generated ran-
domisation lists (using the program ‘Ran-
code +’ (version 3.6) of IDV, Gauting, Ger-
many), which were generated for the five
body weight classes (40-50 kg, 51-60 kg,
61-75 kg, 76-100 kg and 101-128 kg),
each in blocks of four, with medication dis-
tributed to each centre according to this
list”
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Comment: Centralised randomisation in
blocks of 4
Allocation concealment (selection bias) Unclear risk Insufficient information to make judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “To maintain investigator and pa-
tient blinding, patients randomised to
azathioprine received verum azathioprine
tablets and placebo mesalazine tablets;
those randomised to mesalazine received
verum mesalazine tablets and placebo aza-
thioprine tablets”
Comment: a double-blind, double-
dummy RCT
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to make judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The intention-to-treat (ITT) pop-
ulation was defined as all randomised pa-
tients who received 1 dose of study medi-
cation”
Comment:The intention-to-treat (ITT)
population was defined as all randomised
patients who received 1 dose of study med-
ication
Selective reporting (reporting bias) Low risk Trial registration avail-
able (NCT00946946) and all prespecified
outcomes were reported
Other bias Low risk Quote: “Baseline characteristics were simi-
lar between treatment groups apart from a
lowermeanCDAI value in the azathioprine
cohort (70 vs 102 in the mesalazine arm)
and a higher proportion of azathioprine pa-
tients with a penetrating disease behaviour
(66% vs 43%)”
Comment: Some differences at baseline;
study supported by Falk Pharma but con-
flict of interest declared. No other apparent
sources of bias detected
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Methods Study design: RCT, single
Setting: Italy; University Hospital of Genoa; 2008-2010
Participants Inclusion: Adult patients with ileal or ileocolonic CD within 4 weeks of resection of
macroscopically diseased bowel with anastomosis between normal ileum and colon
Exclusion: Patients with (i) more than 10 years of CD requiring first resective surgery
for short (10 cm) fibrostenotic stricture, (ii) macroscopically active disease not resected
at the time of surgery, and (iii) presence of a stoma
Age (IG1 / IG2) median (range): not reported, overall >18; 45 (22 - 66) vs 46 (25 -
65)
Sex (M:F): 25:26 overall; (8:8) vs (9:8) vs (8:10)
Type of surgery: Not reported
Previous surgery (IG1+IG2): one-40 (12/15/13); two-9 (3/2/4); three-2 (1/0/1)
Start of intervention after surgery: 2-4 weeks
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): 19 (9/4/6)
Number randomised (n = 51): 16/17/18
Number analysed (n = 78): (16/16) vs (17/17) vs (18/18)
Post-randomisation exclusion (n = 5): (1/16 ) vs (2/17) vs (2/18) (unclear)
Interventions Group 1: Adalimumab subcutaneous injections 160 / 80 mg at 0 and 2 weeks, followed
by 40 mg every 2 weeks for 2 years
Group 2: Azathioprine (Azafor, Sofar S.P.A.,Milan, Italy), at the dose of 2 mg / kg every
day for 2 years
Group 3: Mesalamine (Pentasa, Ferring S.P.A., Milan, Italy), at the dose of 3 g / day
divided in 3 doses for 2 years
All participants: Patients on antibiotics or immunomodulators at entry into the study
discontinued these medications 12 weeks before surgery. Continuous use of nonsteroidal
anti-inflammatory drugs was not allowed during the study. No other medications were
prescribed except for occasional tablets of paracetamol or tramadol. Patients were sub-
jected to endoscopy at 12 and 24months; small bowel enteroclysis or magnetic resonance
imaging at 12 and 24 months; physical examination with interviews, together with an
extensive battery of blood tests weekly for the first 4 weeks and then every 2 months,
and completed an IBD-Q at 1 month before surgery and at 12 and 24 months aft er
surgery. The CDAI was determined at each study visit. In addition, adverse events were
ascertained at each visit
Outcomes Duration of study: 2 years
1. Clinical recurrence d defined as a score of ≥ 2 on the clinical recurrence grading
scale 1-4 proposed by Hanauer et al
2. Clinical recurrence based on CD activity index (CDAI) was calculated for each
patient and recurrence was set in case of a score > 200, whereas clinical remission was
defined by a CDAI score of < 150
2. Endoscopic recurrence defined by a Rutgeerts score of ≥ i2
3. Radiologic recurrence defined as a score of ≥ 2 on the radiographic recurrence
grading scale (where 1 indicates normal; 2, mucosal edema / aphthoid ulcers; 3, linear
ulcers / cobblestoning; and 4, strictures / fistulas / inflammatory mass)
4. Health-related quality of life
5.Median Lémann Index
5. Adverse events
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Notes Funding source: Supported by research funds of the university
Conflict of interest: Authors declare no conflict of interest
Power calculation: We considered reasonable to hypothesize an endoscopic recurrence
rate of ~ 80%and 15%and a clinical recurrence rate of ~ 65% and 5% for themesalamine
and adalimumab groups, respectively, at 2 years of follow-up. This estimation has been
supported by the results shown in previous trials on postoperative CD relapse. Thus,
based on these data, 13 patients per treatment group resulted to be sufficient to detect a
difference of at least 65 % for endoscopic recurrence and 60 % for clinical recurrence in
favour of the adalimumab group with a power of 80 % (global type I error of 5 % ). Th
e number of patients in each group was increased to 16 to compensate for an anticipated
dropout rate of 15%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible and consenting patients
were assigned randomly using a computer-
generated sequence (www. randomizer.org)
to a regimen of…”
Comment: Computer generated random
sequence
Allocation concealment (selection bias) Low risk Quote: ”Patient allocation was concealed
and performed by an independent nurse
not involved with the trial“
Comment: Probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study is open-label design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”“A blinded investigator (P.D.) re-
viewed each patient’s video-recorded pro-
cedure and provided a separate endoscopic
score” and “At the conclusion of the study,
the principal investigator (E.S.) re-scored
each patient by re-reviewing the video
recordings in a random and blinded man-
ner”
Comment: Assessors were blinded for en-
doscopic assessments only.However, no in-
formation on clinical assessment of relapse
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Statistical analysis was conducted
according to the intention-to-treat prin-
ciple.” Comment: ITT analysis applied.
Withdrawals and reasons reported
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Savarino 2013 (Continued)
Selective reporting (reporting bias) Low risk Trial registration not available, however, all
outcomes stated in the method section re-
ported
Other bias Low risk Quote: “Characteristics were similar for
sex, age, smoking, duration of CD, disease
behavior, disease location, priormedication
exposure, including IFX, and prior surgical
resection.”
Comment: Groups well balanced at base-
line; no other apparent sources of bias de-
tected
Sutherland 1997
Methods Study design: RCT, multicentre
Setting: Italy; University Hospital of Genoa; 2008-2010
Participants Inclusion:Adult patients (18+) with ileal or ileocolonic CDCD location restrictions not
mentioned. CD in remission for 1 month, but at least 2 flare-ups within the last 4 years,
one within the last 18 months or a recent resection. Remission defined as CDAI<150 at
baseline and no symptoms within last 30 days. No steroid use within a month of study
Exclusion: CDAI >150; previous total proctocolectomy, short-bowel syndrome, more
than 3 resections within 10 years, chronic perianal disease, ulcer colitis, stool positive
for pathogens, parasites or toxins; drug or alcohol abuse, clinically significant hepatic
neurological, endocrine, renal, or other major systemic disease that would make imple-
mentation or interpretation of the protocol or results difficult; any history of cancer,
allergy to aspirin or Mesalamine; patients on immunosuppressants therapy within last
90 days, or corticosteroids within last 30 days or Mesalamine/metronidazole within last
7 days before resection
Age (IG1 / IG2) mean (±SE): 36.5 (0.7) overall; 29.7 (1.1) vs 29.0 (1.0)
Sex (M:F): 106:140 overall; (48:70) vs (58:70)
Type of surgery: not reported
Previous surgery (IG1+IG2): not reported
Start of intervention after surgery: 2-4 weeks
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): not reported
Number randomised (n = 66): 31/35 (total number of randomised is 293 of which
180 have medically induced remission and 66 with surgically-induced remission; data
presented for the later only)
Number analysed (n = 66): (31/31) vs (35/35)
Post-randomisation exclusion (n = 7): not presented separately for patients with sur-
gical remission
Interventions Group 1: 3 capsules of 250 mg Mesalamine 4 times a day
Group 2: 3 capsules of 250 mg Placebo 3g/day for 4 times a day
All participants: No steroid, other mesalamine preparations, aspirin or other nons-
teroidal anti-inflammatory drugs; immunosuppressives, narcotics except codeine or lop-
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Sutherland 1997 (Continued)
eradime, antibiotics for longer than 14 days
Outcomes Duration of study: 12 months
1.Clinical recurrence defined as first occurrence of a CDAI that was >150 as well as the
absolute value of at least 60 points higher than baseline or where physician diagnosed a
flare-up of disease but a full diary card was not available for the calculation of the final
CDAI
Notes Funding source: supported by research funds of the university
Conflict of interest: Authors declare no conflict of interest
Power calculation: It was hypothesized that the relapse rate for mesalamine-treated
patients would be 25%. Assuming an α of 0.05 and a β of 0.20 (power of 0.80), a
two-tailed sample size calculation determined that 150 patients were required for each
treatment group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomisation was performed ac-
cording to a computer generated randomi-
sation scheme by the study sponsor
Comment: Computer generated randomi-
sation scheme
Allocation concealment (selection bias) Low risk Quote:“For each patient, the identity of the
study medication was concealed in an in-
dividual sealed envelope sent with the drug
supplies” “Medication was packaged by the
sponsor and dispensed to each centre on
coded identical-appearing boxes”
Comment: sequentially numbered drug
packages of identical appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Medication was packaged by the
sponsor and dispensed to each centre on
coded identical-appearing boxes”
Comment: double blinded placebo con-
trolled trial. Probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to make judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition rates were not specifically re-
ported for the sub-population of interest in
our review (surgical group)
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Sutherland 1997 (Continued)
Selective reporting (reporting bias) Low risk Although adverse event data were not avail-
able for the sub-population of interest in
our review (surgical group), all expected
outcomes appear to have been reported for
the entire population
Other bias Low risk The demographic characteristics and dis-
ease milestones for the patients are shown
in Table 2. There were no significant differ-
ences between themesalamine and placebo
treated groups.Supported by a grant by
Marrion Merrill Dow. Author contacted
and confirmed company had no part in the
design, analysis or write up
Wenckert 1978
Methods Study design: RCT, multicentre
Setting: Sweden and Denmark
Participants Inclusion:Noage restrictionsmentioned.CDof small and / or large bowel, first resection
and supporting histological evidence of active CD in resected specimens. ESR had to
return to normal within 6 weeks of operation, no further remission criteria defined. No
steroid use allowed
Exclusion:Treatment with a by-pass, doubtful diagnosis, allergy on salazopyrin or acetyl-
salicylic acid, abnormal ESR 6 weeks after operation, lack of cooperation, treatment with
corticosteroids or immunosuppressive drugs
Age (IG1 / IG2) median: 24.5 overall
Sex (M:F): 33:33 overall
Type of surgery: Not reported
Previous surgery (IG1+IG2): n/a
Start of intervention after surgery: 2-4 weeks
Medication use (IG1+ IG2): Not reported
Smoker (IG1 / IG2): Not reported
Number randomised (n = 66): 32/34
Number analysed (n = 66): (32/32) vs (34/34)
Post-randomisation exclusion (n = 4/66): (2/32) vs (2/36)
Interventions Group 1: Salazopyrin 3 g/day for 18 months
Group 2: placebo 3 g/day for 18 months
All participants: Other specific treatment was avoided. Relapse free patients were ob-
served for 24 months
Outcomes 1. Relapse was defined clinically, based on the information from special control charts
on the presence/absence of fever, diarrhoea, rectal bleeding, abdominal pain, extra-in-
testinal manifestations, palpable abdominal masses, fistulae, abscesses and possible loss
of working days. The relapses were not based on index calculation
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Wenckert 1978 (Continued)
Notes Funding source: Not reported
Conflict of interest: Not reported
Power calculation: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The experimental design was dou-
ble blind multicentre trial with block-ran-
domisation, and no cross-over.”Comment:
insufficient data to make judgement. How-
ever, author contacted and confirmed that
block randomisation described was carried
out in accordance with established accept-
able randomisation methodology
Allocation concealment (selection bias) Unclear risk Comment: insufficient data tomake judge-
ment The author was contacted, but was
not able to give further details on this issue
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient data tomake judge-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient data tomake judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for those missing, balanced
between study groups, reasons for with-
drawal unlikely to be related to true out-
come
Selective reporting (reporting bias) Unclear risk The study includes results for adverse
events, but these are not reported clearly
enough to allow analysis and permit a
judgement as to the risk of bias to be made
Other bias Unclear risk Insufficient
information to ascertain whether baseline
characteristics were balanced
ADA: Adalimumab;AZA; Azathioprine;CD: Crohn’s disease; CDAI: Crohn’s disease activity index; cm: centimetre;dL; decilitre; ESR:
erythrocyte sedimentation rate; F: female; g: gram; IFX: Infliximab; ITT: intention-to-treat; IBDQ: inflammatory bowel disease
questionnaire; IG; intervention group; kg: kilogram; L; litres;M:male;MES;mesala(m/z)ine;mg:miligram;m:month; SD: standard
deviation SE: standard error; µmol: micromole; y: years
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dumois 2001 Not randomised controlled trial - comment on already published trial
Ewe 1981 Not randomised controlled trial
ISRCTN84003996 Wrong population - medically-induced not surgically-induced remission
McLeod 1997 Not randomised controlled trial; non-randomised follow-up of included study
NCT00225810 Wrong population - active disease
NCT00245505 Study terminated due to lack of eligible participants
NCT00300118 Wrong population - active disease
NCT01696942 Terminated, lack of accrual
Orlando 2012 Not a randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
NCT00976690
Methods RCT
Participants Adults (> 18 years) with Crohn’s disease who had ileocolonic or colon resection 21 days before inclusion, must have
clinical remission at inclusion (CDAI < 150)
Resection > 50 cm or subtotal colectomy with ileorectal anastomosis
Interventions Azathioprine : 2 mg/kg/day
Mesalazine : 4 g/day
Outcomes Clinical and endoscopic recurrence at 12 and 24 months
Notes Study completed, authors were contacted, report in preparation for publication
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. 5-ASA versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 12 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Adverse events at 12 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Withdrawals due to adverse
events at 12 months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. 5-ASA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 48 weeks to
72 months
5 730 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.72, 0.96]
2 Endoscopic recurrence at 12
weeks to 72 months
3 537 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.56, 1.24]
3 Adverse events at 12 weeks to 72
months
4 466 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.60, 1.91]
4 Serious adverse events at 48
weeks to 72 months
3 577 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.44, 2.59]
5 Withdrawal due to adverse
events at 12 weeks to 72
months
3 297 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.71, 3.19]
Comparison 3. High versus low dose 5-ASA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 12 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Endoscopic recurrence at 12
months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Adverse events at 12 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Adverse events leading to
withdrawal at 12 months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Comparison 4. 5-ASA versus purine antimetabolites
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 24 months 4 347 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.76, 1.07]
2 Endoscopic recurrence at 24
months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Radiologic relapse at 24 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Surgical relapse at 24 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Adverse events at 52 weeks to 24
months
5 425 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.97, 1.27]
6 Serious adverse events at 52
weeks to 24 months
3 311 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.11, 0.80]
7 Withdrawal due to adverse
events at 52 weeks to 24
months
5 425 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.28, 0.83]
8 HRQoL (IBDQ score >170 at
24 months)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 HRQoL (mean IBDQ score
change at 52 weeks)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 5. 5-ASA versus anti TNF-
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 24 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Endoscopic recurrence at 24
months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Radiologic relapse at 24 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Adverse events at 24 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Withdrawal due to adverse
events at 24 months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 HRQoL (IBDQ >170) 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Sulphasalazine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical relapse at 18 to 36
months
2 298 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.56, 1.38]
2 Withdrawal due to adverse
events at 18 months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 5-ASA versus no treatment, Outcome 1 Clinical relapse at 12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 5-ASA versus no treatment
Outcome: 1 Clinical relapse at 12 months
Study or subgroup 5-ASA No treatment Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 1994 20/55 28/55 0.71 [ 0.46, 1.10 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours no treatment
Analysis 1.2. Comparison 1 5-ASA versus no treatment, Outcome 2 Adverse events at 12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 5-ASA versus no treatment
Outcome: 2 Adverse events at 12 months
Study or subgroup 5-ASA No treatment Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 1994 2/55 0/55 5.00 [ 0.25, 101.81 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours no treatment
73Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 5-ASA versus no treatment, Outcome 3 Withdrawals due to adverse events at
12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 1 5-ASA versus no treatment
Outcome: 3 Withdrawals due to adverse events at 12 months
Study or subgroup 5-ASA No treatment Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 1994 2/55 0/55 5.00 [ 0.25, 101.81 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours no treatment
Analysis 2.1. Comparison 2 5-ASA versus placebo, Outcome 1 Clinical relapse at 48 weeks to 72 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 5-ASA versus placebo
Outcome: 1 Clinical relapse at 48 weeks to 72 months
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brignola 1995 13/44 14/43 5.5 % 0.91 [ 0.48, 1.70 ]
Hanauer 2004 33/44 35/40 50.7 % 0.86 [ 0.70, 1.05 ]
Lochs 2000 47/154 59/170 21.9 % 0.88 [ 0.64, 1.21 ]
McLeod 1995 35/88 44/81 20.5 % 0.73 [ 0.53, 1.01 ]
Sutherland 1997 3/31 8/35 1.4 % 0.42 [ 0.12, 1.46 ]
Total (95% CI) 361 369 100.0 % 0.83 [ 0.72, 0.96 ]
Total events: 131 (5-ASA), 160 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.07, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.013)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours 5-ASA Favours placebo
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Analysis 2.2. Comparison 2 5-ASA versus placebo, Outcome 2 Endoscopic recurrence at 12 weeks to 72
months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 5-ASA versus placebo
Outcome: 2 Endoscopic recurrence at 12 weeks to 72 months
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brignola 1995 12/44 25/43 23.5 % 0.47 [ 0.27, 0.81 ]
Florent 1996 38/65 40/61 35.2 % 0.89 [ 0.68, 1.17 ]
Lochs 2000 133/154 134/170 41.3 % 1.10 [ 0.99, 1.21 ]
Total (95% CI) 263 274 100.0 % 0.83 [ 0.56, 1.24 ]
Total events: 183 (5-ASA), 199 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 12.85, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours placebo
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Analysis 2.3. Comparison 2 5-ASA versus placebo, Outcome 3 Adverse events at 12 weeks to 72 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 5-ASA versus placebo
Outcome: 3 Adverse events at 12 weeks to 72 months
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brignola 1995 5/44 3/43 18.1 % 1.63 [ 0.41, 6.40 ]
Florent 1996 5/65 3/61 17.6 % 1.56 [ 0.39, 6.27 ]
Hanauer 2004 6/44 4/40 23.9 % 1.36 [ 0.41, 4.48 ]
McLeod 1995 7/88 10/81 40.3 % 0.64 [ 0.26, 1.61 ]
Total (95% CI) 241 225 100.0 % 1.07 [ 0.60, 1.91 ]
Total events: 23 (5-ASA), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.98, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours placebo
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Analysis 2.4. Comparison 2 5-ASA versus placebo, Outcome 4 Serious adverse events at 48 weeks to 72
months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 5-ASA versus placebo
Outcome: 4 Serious adverse events at 48 weeks to 72 months
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanauer 2004 0/44 0/40 Not estimable
Lochs 2000 8/154 9/170 92.2 % 0.98 [ 0.39, 2.48 ]
McLeod 1995 1/88 0/81 7.8 % 2.76 [ 0.11, 66.90 ]
Total (95% CI) 286 291 100.0 % 1.06 [ 0.44, 2.59 ]
Total events: 9 (5-ASA), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours placebo
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Analysis 2.5. Comparison 2 5-ASA versus placebo, Outcome 5 Withdrawal due to adverse events at 12
weeks to 72 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 2 5-ASA versus placebo
Outcome: 5 Withdrawal due to adverse events at 12 weeks to 72 months
Study or subgroup 5-ASA Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brignola 1995 5/44 3/43 30.4 % 1.63 [ 0.41, 6.40 ]
Florent 1996 5/65 3/61 29.5 % 1.56 [ 0.39, 6.27 ]
Hanauer 2004 6/44 4/40 40.1 % 1.36 [ 0.41, 4.48 ]
Total (95% CI) 153 144 100.0 % 1.50 [ 0.71, 3.19 ]
Total events: 16 (5-ASA), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours placebo
Analysis 3.1. Comparison 3 High versus low dose 5-ASA, Outcome 1 Clinical relapse at 12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 High versus low dose 5-ASA
Outcome: 1 Clinical relapse at 12 months
Study or subgroup Mesalamine 4g/d Mesalamine 2.4 g/d Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 2003 17/101 27/105 0.65 [ 0.38, 1.13 ]
0.01 0.1 1 10 100
Mesalamine 4g/d Mesalamine 2.4 g/d
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Analysis 3.2. Comparison 3 High versus low dose 5-ASA, Outcome 2 Endoscopic recurrence at 12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 High versus low dose 5-ASA
Outcome: 2 Endoscopic recurrence at 12 months
Study or subgroup Mesalamine 4g/d Mesalamine 2.4 g/d Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 2003 45/101 59/105 0.79 [ 0.60, 1.04 ]
0.01 0.1 1 10 100
Mesalamine 4g/d Mesalamine 2.4 g/d
Analysis 3.3. Comparison 3 High versus low dose 5-ASA, Outcome 3 Adverse events at 12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 High versus low dose 5-ASA
Outcome: 3 Adverse events at 12 months
Study or subgroup Mesalamine 4g/d Mesalamine 2.4 g/d Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 2003 2/101 2/105 1.04 [ 0.15, 7.24 ]
0.01 0.1 1 10 100
Mesalamine 4g/d Mesalamine 2.4 g/d
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Analysis 3.4. Comparison 3 High versus low dose 5-ASA, Outcome 4 Adverse events leading to withdrawal
at 12 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 3 High versus low dose 5-ASA
Outcome: 4 Adverse events leading to withdrawal at 12 months
Study or subgroup Mesalamine 4g/d Mesalamine 2.4 g/d Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprilli 2003 2/101 2/105 1.04 [ 0.15, 7.24 ]
0.01 0.1 1 10 100
Mesalamine 4 g/d Mesalamine 2.4 g/d
Analysis 4.1. Comparison 4 5-ASA versus purine antimetabolites, Outcome 1 Clinical relapse at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 1 Clinical relapse at 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ardizzone 2004 32/71 35/71 19.0 % 0.91 [ 0.65, 1.30 ]
Hanauer 2004 33/44 32/47 29.2 % 1.10 [ 0.85, 1.43 ]
Herfarth 2006 29/37 39/42 42.5 % 0.84 [ 0.70, 1.02 ]
Savarino 2013 9/18 13/17 9.3 % 0.65 [ 0.38, 1.11 ]
Total (95% CI) 170 177 100.0 % 0.90 [ 0.76, 1.07 ]
Total events: 103 (5-ASA), 119 (Purine antimetabolites)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.18, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours purine antimetabo
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Analysis 4.2. Comparison 4 5-ASA versus purine antimetabolites, Outcome 2 Endoscopic recurrence at 24
months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 2 Endoscopic recurrence at 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 15/18 11/17 1.29 [ 0.86, 1.94 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours purine antimetabo
Analysis 4.3. Comparison 4 5-ASA versus purine antimetabolites, Outcome 3 Radiologic relapse at 24
months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 3 Radiologic relapse at 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 15/18 13/17 1.09 [ 0.78, 1.52 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours purine antimetabo
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Analysis 4.4. Comparison 4 5-ASA versus purine antimetabolites, Outcome 4 Surgical relapse at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 4 Surgical relapse at 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ardizzone 2004 26/71 21/71 1.24 [ 0.77, 1.98 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours purine antimetabo
Analysis 4.5. Comparison 4 5-ASA versus purine antimetabolites, Outcome 5 Adverse events at 52 weeks
to 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 5 Adverse events at 52 weeks to 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ardizzone 2004 27/71 18/71 7.5 % 1.50 [ 0.91, 2.47 ]
Hanauer 2004 6/44 9/47 2.1 % 0.71 [ 0.28, 1.84 ]
Herfarth 2006 26/37 29/42 21.7 % 1.02 [ 0.76, 1.36 ]
Reinisch 2010 34/37 32/41 51.9 % 1.18 [ 0.98, 1.42 ]
Savarino 2013 14/18 14/17 16.9 % 0.94 [ 0.68, 1.31 ]
Total (95% CI) 207 218 100.0 % 1.11 [ 0.97, 1.27 ]
Total events: 107 (5-ASA), 102 (Purine antimetabolites)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.90, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5-ASA Favours purine antimetabo
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Analysis 4.6. Comparison 4 5-ASA versus purine antimetabolites, Outcome 6 Serious adverse events at 52
weeks to 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 6 Serious adverse events at 52 weeks to 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ardizzone 2004 6/71 15/71 77.9 % 0.40 [ 0.16, 0.97 ]
Hanauer 2004 0/44 2/47 10.3 % 0.21 [ 0.01, 4.32 ]
Reinisch 2010 0/37 10/41 11.8 % 0.05 [ 0.00, 0.87 ]
Total (95% CI) 152 159 100.0 % 0.30 [ 0.11, 0.80 ]
Total events: 6 (5-ASA), 27 (Purine antimetabolites)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.20, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
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Favours 5-ASA Favours purine antimetabo
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Analysis 4.7. Comparison 4 5-ASA versus purine antimetabolites, Outcome 7 Withdrawal due to adverse
events at 52 weeks to 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 7 Withdrawal due to adverse events at 52 weeks to 24 months
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ardizzone 2004 6/71 15/71 36.3 % 0.40 [ 0.16, 0.97 ]
Hanauer 2004 6/44 9/47 31.9 % 0.71 [ 0.28, 1.84 ]
Herfarth 2006 4/37 7/42 21.8 % 0.65 [ 0.21, 2.04 ]
Reinisch 2010 1/37 10/41 7.1 % 0.11 [ 0.01, 0.82 ]
Savarino 2013 0/18 1/17 2.9 % 0.32 [ 0.01, 7.26 ]
Total (95% CI) 207 218 100.0 % 0.48 [ 0.28, 0.83 ]
Total events: 17 (5-ASA), 42 (Purine antimetabolites)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.36, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0079)
Test for subgroup differences: Not applicable
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Favours 5-ASA Favours purine antimetabo
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Analysis 4.8. Comparison 4 5-ASA versus purine antimetabolites, Outcome 8 HRQoL (IBDQ score >170 at
24 months).
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 8 HRQoL (IBDQ score >170 at 24 months)
Study or subgroup 5-ASA
Purine an-
timetabo-
lites Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 3/18 2/17 1.42 [ 0.27, 7.46 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours purine antimetabo
Analysis 4.9. Comparison 4 5-ASA versus purine antimetabolites, Outcome 9 HRQoL (mean IBDQ score
change at 52 weeks).
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 4 5-ASA versus purine antimetabolites
Outcome: 9 HRQoL (mean IBDQ score change at 52 weeks)
Study or subgroup 5-ASA
Purine an-
timetabo-
lites
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Reinisch 2010 37 5 (27.4) 41 9 (17.7) -4.00 [ -14.36, 6.36 ]
-100 -50 0 50 100
Favours 5-ASA Favours purine antimetabo
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Analysis 5.1. Comparison 5 5-ASA versus anti TNF-
, Outcome 1 Clinical relapse at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 5 5-ASA versus anti TNF-
Outcome: 1 Clinical relapse at 24 months
Study or subgroup 5-ASA anti TNF- Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 9/18 2/16 4.00 [ 1.01, 15.84 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours anti TNF-
Analysis 5.2. Comparison 5 5-ASA versus anti TNF-
, Outcome 2 Endoscopic recurrence at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 5 5-ASA versus anti TNF-
Outcome: 2 Endoscopic recurrence at 24 months
Study or subgroup 5-ASA anti TNF- Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 15/18 1/16 13.33 [ 1.98, 89.95 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours anti TNF-
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Analysis 5.3. Comparison 5 5-ASA versus anti TNF-
, Outcome 3 Radiologic relapse at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 5 5-ASA versus anti TNF-
Outcome: 3 Radiologic relapse at 24 months
Study or subgroup 5-ASA anti TNF- Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 15/18 1/16 13.33 [ 1.98, 89.95 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours anti TNF-
Analysis 5.4. Comparison 5 5-ASA versus anti TNF-
, Outcome 4 Adverse events at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 5 5-ASA versus anti TNF-
Outcome: 4 Adverse events at 24 months
Study or subgroup 5-ASA anti TNF- Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 14/18 11/16 1.13 [ 0.75, 1.71 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours anti TNF-
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Analysis 5.5. Comparison 5 5-ASA versus anti TNF-
, Outcome 5 Withdrawal due to adverse events at 24 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 5 5-ASA versus anti TNF-
Outcome: 5 Withdrawal due to adverse events at 24 months
Study or subgroup 5-ASA anti TNF- Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 0/18 1/16 0.30 [ 0.01, 6.84 ]
0.01 0.1 1 10 100
Favours 5-ASA Favours anti TNF-
Analysis 5.6. Comparison 5 5-ASA versus anti TNF-
, Outcome 6 HRQoL (IBDQ >170).
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 5 5-ASA versus anti TNF-
Outcome: 6 HRQoL (IBDQ >170)
Study or subgroup 5-ASA anti TNF- Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Savarino 2013 3/18 14/16 0.19 [ 0.07, 0.54 ]
0.01 0.1 1 10 100
Favours anti TNF- Favours 5-ASA
88Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 Sulphasalazine versus placebo, Outcome 1 Clinical relapse at 18 to 36 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 6 Sulphasalazine versus placebo
Outcome: 1 Clinical relapse at 18 to 36 months
Study or subgroup Sulphasalazine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wenckert 1978 6/32 11/34 20.5 % 0.58 [ 0.24, 1.38 ]
Ewe 1989 89/111 99/121 79.5 % 0.98 [ 0.86, 1.11 ]
Total (95% CI) 143 155 100.0 % 0.88 [ 0.56, 1.38 ]
Total events: 95 (Sulphasalazine), 110 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Sulphasalazine Favours Placebo
Analysis 6.2. Comparison 6 Sulphasalazine versus placebo, Outcome 2Withdrawal due to adverse events at
18 months.
Review: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease
Comparison: 6 Sulphasalazine versus placebo
Outcome: 2 Withdrawal due to adverse events at 18 months
Study or subgroup Sulphasalazine Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wenckert 1978 0/32 1/34 0.35 [ 0.01, 8.38 ]
0.01 0.1 1 10 100
Favours Sulphasalazine Favours Placebo
89Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table 1. Summury of interventions and outcomes
Study ID Group 1 Group 2 Group 3 Relapse Health-
related qual-
ity of life def-
inition
Adverse
Events/
Serious
adverse
events/ With-
drawal
Ardizzone
2004
Mesalamine
(3 g/day)
Azathioprine
(2 mg/kg/day)
Clinical: 32/
71 vs. 35/71
Surgical: 25/
71 vs. 18/71
AE: 27/71 vs.
18/71
SAE: 6/71 vs.
15/71
Withdrawal:
6/71 vs. 15/71
Brignola 1995 Mesalamine
(3 g/day)
Placebo
tablets
Clinical: 13/
44 vs. 14/43
5/44 vs. 3/43
Caprilli 1994 Mesalamine
(2.4 g/day)
No treatment Relapse: 20/
55 vs. 28/55
Withdrawal:
2/55 vs. 2/55
Caprilli 2003 Mesalazine
(4 g/day)
Mesalazine
(2.4 g/day)
Clinical: 17/
101 vs. 27/
101
Endoscopic
>1: 45/101 vs.
59/105
With-
drawal: 2/101
vs. 2/105
Ewe 1989 Sulfasalazine
(3 g/day)
Placebo Relapse:
Total
0-36 months:
89/111 vs. 99/
121
N/A
Florent 1996 Claver-
sal (1000 mg/
day)
Placebo
(1000 mg/
day)
En-
doscopic: 38/
65 vs. 40/61
Withdrawal:
5/65 vs. 3/61
Hanauer 2004 6-Mercaptop-
urine (50 mg/
day)
Mesalamine
(3 g/day)
Placebo Clinical: 32/
47 vs. 33/44
vs.35/40
Endoscopic
rate: % (CI)
Radiographic
rate: % (CI)
AE:9/47 vs. 6/
44 vs. 4/40
SAE: 2/47 vs.
0/44 vs. 0/40
Lochs 2000 Mesalamine
(4 g/day)
Placebo Clinical: 47/
154 vs. 59/
170
SAE: 8/154
vs. 9/170
90Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Summury of interventions and outcomes (Continued)
Endo-
scopic: 133/
154 vs. 134/
170
McLeod 1995 Mesalamine
(3 g/day)
Placebo Symptomatic
relapse: 35/88
vs. 44/81
Endo-
scopic and ra-
diologic rate:
significantly
decreased in
Group1
AE: 7/88 vs.
10/81
SAE: 1/88 vs.
0/81
Reinisch 2010 Aza-
thioprine (2.0
to 2.5 mg/kg/
day) + Placebo
mesalazine
Mesalazine (4
g/day) +
Placebo
azathioprine
Not included Mean IBDQ
change com-
pared to base-
line
AE: 34/37 vs.
32/41
SAE: 0/37 vs.
10/41
Withdrawal:
1/37 vs. 10/41
Savarino 2013 Adal-
imumab (160
mg at week 0,
80 mg at 2
weeks and 40
mg/week
thereafter)
Azathioprine
(2 mg/kg/day)
Mesalamine
(3 g/day)
Clini-
cal by CDAI:
1/16 vs.12/17
vs. 9/18
Endoscopic:
1/16 vs. 11/17
vs. 15/18
Radiologic:
1/16 vs. 13/17
vs. 15/18
IBDQ >170:
14/16 vs 2/17
vs 3/18
AE:11/16 vs.
14/17 vs. 14/
18
Withdrawal:
1/16 vs. 1/17
vs. 0/18
Sutherland
1997
Mesalamine
(3 g/day)
Placebo Clinical: 3/31
vs.8/35
IBDQ score:
significant de-
cline in both
groups
N/A
Wenckert
1978
Suphasalazine
(3 g/day)
Placebo Clinical: 6/32
vs. 11/34
Withdrawal:
0/32 vs. 1/34
AE = adverse events; CDAI = Crohn’s disease activity index; ; g = gram; IBDQ = inflammatory bowel disease questionnaire; mg =
milligram; N/A = not applicable; SAE = serious adverse events;
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Table 2. Key study characteristics
Comparison Study Time from surgery
till recruitment
Site of surgery % /
*exclusion criteria
Clinical relapse def-
inition
Endoscopic / his-
tological recurrence
definition/ other
Sulfasalazine vs Placebo
SFZ 3 g/day Ewe 1989 Immediately after
surgery
Ileocolon 92; Ileum
2; colon 6
*non-standard pol-
icy resection (radical
or non-radical)
Proven by radiology,
endoscopy or opera-
tion
N/A
SFZ 3 g/day vs.
placebo
Wenckert 1978 2-4 weeks N/A Special control
charts
N/A
5-ASA vs no treatment
MES 2.4 g/day (24
mo)
Caprilli 1994 2 weeks Not reported
*disease localisa-
tion to the jejunum,
proximal ileum, left
colon or ano-rectum
CDAI >150 N/A
5-asa vs placebo
MES 3 g/day
vs. placebo
Brignola 1995 ≤ 1 month Ileum 56, ileocaecal
46
*surgery other than
in ileal or ileocaecal
region
CDAI >150 Standardised
form for description
of endoscopic lesions
by type and charac-
teristics
MES 1.5 g/day vs.
Placebo
Florent 1996 2 weeks Ileal
44 ; colonic 6; ileo-
colonic 48; Anoper-
ineal lesion 12.
* permanent stoma,
small intestinal re-
section of more than
100 cm prior to the
pretrial operation
N/A Rutgeerts i ≥ 1
MES 3 g/day vs.
placebo
Hanauer 2004 Before postoperative
hospital discharge
Not reported
* Active perianal dis-
ease or any active
disease in other seg-
ments of the intes-
tine
Clinical recurrence
grading >2
Rutgeerts i > 2
Radiographic re-
lapse: radiographic
recurrence grading >
2
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Table 2. Key study characteristics (Continued)
MES 4 g/day vs.
placebo
Lochs 2000 < 10 days IIeal 49; ileocolonic
56, colonic 5.
* short bowel syn-
drome, presence of
an ileocolonic stoma,
more than 3 surg-
eries
CDAI > 250 and
CDAI >200 but min
60 points increase
for 2 weeks
Rutgeerts i ≥ 2
Ileum 50, MES 3 g/
day vs. placebo
McLeod 1995 ≤ 8 week IIeal 21; ileocolonic
46, colonic 33.
Severe symptoms to
warrant
treatment and radio-
logical or endoscopic
evidence of disease
Presence of endo-
scopic or radiologi-
cal evidence of dis-
ease and included
both asymptomatic
and symptomatic pa-
tients
MES 3 g/day vs.
placebo
Sutherland 1997 2-4 weeks Ileal 49, ileocolonic
50, unknown 1
CDAI >150 as well
as the absolute value
of at least 60 points
higher than baseline
N/A
HRQL: IBDQ
5-ASA vs AZA or 6-MP
MES 3 mg/kg/day
vs. AZA 2 mg/kg/
day
Ardizzone 2004 Max 2 weeks Small bowel only 25.
3; Colon 5.6; Small
bowel and colon 9.8;
upper gastrointesti-
nal tract 16.2
*surgical procedures
other than conserva-
tive surgery or for pe-
rianal disease only
CDAI >200 N/A
Surgical relapse:
need for another sur-
gical procedure
MES 3 g/day vs. 6-
MP 50 mg/day
Hanauer 2004 before postoperative
hospital discharge
Not reported
* Active perianal dis-
ease or any active
disease in other seg-
ments of the intes-
tine
Clinical recurrence
grading >2 (Hanauer
et al)
Rutgeerts i ≥ 2
Radiographic re-
lapse: radiographic
recurrence grading >
2
MES 4g/
day vs. AZA 2 mg/
kg/day (52 weeks)
Reinisch 2010 6-24 months Not reported
* Short
bowel syndrome, an
ileocolonic stoma
CDAI >200 Rutgeerts i ≥ 2
HRQL: IBDQ
MEZ 3 g/day vs.
AZA 2 mg/kg/day
Savarino 2013 2-4 weeks Ileum 49,
Ileocolonic 51
* fibrostenotic stric-
ture, macroscop-
1. ≥ 2 clinical recur-
rence grading scale (
Hanauer et al)
2. CDAI > 200
Rutgeerts i ≥ 2
Ra-
diologic relapse: ≥
2 radiographic recur-
93Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Key study characteristics (Continued)
ically active disease
not resected at the
time of surgery, and
presence of a stoma
rence grading scale
HRQL: IBDQ >
170
5-ASA vs anti TNF-α
MEZ 3 g/day vs.
Adalimumab
Savarino 2013 2-4 weeks Ileum 49,
Ileocolonic 51
* fibrostenotic stric-
ture, macroscop-
ically active disease
not resected at the
time of surgery, and
presence of a stoma
1. ≥ 2 on the clin-
ical recurrence grad-
ing scale by Hanauer
2. CDAI >200
Rutgeerts i ≥ 2
Ra-
diologic relapse: ≥
2 radiographic recur-
rence grading scale
HRQL: IBDQ >
170
5-ASA VS 5-ASA
4.0 g/day MES vs.
2.4 g/day MES (12
months)
Caprilli 2003 2 weeks Ileum64; Ileum/cae-
cum/ascending
colon 36
* disease localization
to jejunum, proxi-
mal ileum, transverse
colon, left colon or
anorectum
CDAI > 150 points
or an increase in
CDAI score of + 100
points from baseline
Rutgeerts i ≥ 1
g = gram; mg = milligram; kg = kilogram; SFZ = sulphasalazine; MES = mesalamine; MEZ = mesalazine; 6-MP = 6-mercaptopurine;
IBDQ = inflammatory bowel disease questionnaire; HRQL = health related quality of life; N/A = not applicable
AZA = azathioprine; CDAI = Crohn’s disease activity index
A P P E N D I C E S
Appendix 1. Search strategies
Embase
1 random$.tw.
2 factorial$.tw.
3 (crossover$ or cross over$ or cross-over$).tw.
4 placebo$.tw.
5 single blind.mp.
6 double blind.mp.
7 triple blind.mp.
8 (singl$ adj blind$).tw.
9 (double$ adj blind$).tw.
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10 (tripl$ adj blind$).tw.
11 assign$.tw.
12 allocat$.tw.
13 crossover procedure/
14 double blind procedure/
15 single blind procedure/
16 triple blind procedure/
17 randomized controlled trial/
18 or/1-17
19 exp Crohn disease/
20 exp Inflammatory bowel diseases/
21 exp ileitis/
22 regional enteritis.mp.
23 or/19-22
24 exp mesalamine/
25 exp Sulfasalazine/
26 (aminosalicylic acid OR aminosalicylate).mp.
27 (mesalazine OR mesalamine).mp.
28 5-ASA.mp.
29 olsalazine.mp.
30 balsalazide.mp.
31 sulfasalazine.mp.
32 or/24-31
33 (surgery OR surgical OR surgically).mp.
34 surgic*.mp.
35 (post-surgical OR post-surgery).mp.
36 (postoperative OR post-operative).mp.
37 resection*.mp.
38 operation*.mp.
39 or/33-38
40 18 and 23 and 32 and 39
MEDLINE
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. randomized controlled trial/
14. or/1-13
15 exp Crohn disease/
16 exp Inflammatory bowel diseases/
17 exp ileitis/
18 regional enteritis.mp.
19 or/15-18
20 exp mesalamine/
21 exp sulfasalazine/
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22 (aminosalicylic acid OR aminosalicylate).mp.
23 (mesalazine OR mesalamine).mp.
24 5-ASA.mp.
25 olsalazine.mp.
26 balsalazide.mp.
27 sulfasalazine.mp.
28 or/20-27
29 (surgery OR surgical OR surgically).mp.
30 surgic*.mp.
31 (post-surgical OR post-surgery).mp.
32 (postoperative OR post-operative).mp.
33 resection*.mp.
34 operation*.mp.
35 or/29-34
36 14 and 19 and 28 and 35
CENTRAL
#1 MeSH descriptor: [Crohn’s Disease] explode all trees
#2 MeSH descriptor: [Ileitis] explode all trees
#3 MeSH descriptor: [Inflammatory Bowel Disease] explode all trees
#4 Regional enteritis
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Mesalamine] explode all trees
#7 aminosalicylic acid OR aminosalicylate* OR 5-ASA OR 5ASA OR mesalazine OR mesalamine
#8 olsalazine OR balsalazide OR sulfasalazine
#9 #6 or #7 or #8
#10 surgery OR surgic*
#11 post-surgical OR post-surgery
#12 post-operative OR postoperative
#13 resection* OR operation*
#14 #10 or #11 or #12 or #13
#15 #5 and #9 and #14
Cochrane IBD Group Specialized Register
Title and abstract search (Aminosalicylate and Crohn’s Disease OR Mesalazine and Crohn’s Disease OR 5-ASA and Crohn’s Disease)
Clinicaltrials.gov
1. Aminosalicylate and Crohn’s Disease
2. Mesalazine and Crohn’s Disease
WHO trial registry
1. Aminosalicylate and Crohn’s Disease
2. Mesalazine and Crohn’s Disease
WH A T ’ S N E W
Date Event Description
16 July 2018 New search has been performed New search and new studies added
16 July 2018 New citation required but conclusions have not changed Updated review with new authors
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H I S T O R Y
Protocol first published: Issue 3, 2010
Review first published: Issue 1, 2011
Date Event Description
3 December 2010 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Teuta Gjuladin-Hellon performed screening of abstracts and titles, data extraction, risk of bias assessments, statistical analyses,
manuscript preparation, GRADE analysis, critical revision for the manuscript and approval of the final manuscript.
Morris Gordon provided methodological expertise and performed screening of abstracts and titles, screening of full-text articles and
was involved with adjudication of GRADE analysis, manuscript preparation, data interpretation, critical revision of the manuscript,
and approval of the final manuscript.
Anthony K Akobeng provided methodological expertise and was involved with checking the data analyses, critical revision for the
manuscript, and approval of the final manuscript.
Zipporah Iheozor-Ejiofor performed adjudication in the screening and data extraction phases, data extraction, communication with
primary study authors, risk of bias assessments, GRADE analysis, manuscript preparation, critical revision for the manuscript and
approval of the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
Teuta Gjuladin-Hellon: None known.
Morris Gordon has received travel fees to attend international scientific and training meeting such as DDW, Advances in IBD,
ESPGHAN, BSPGHAN and Cochrane focused international events from companies including: Abbott, Nutricia, Biogaia, Ferring,
Allergan, and Tillots.
Zipporah Iheozor-Ejiofor: None known.
Anthony K Akobeng: None known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since the original review in 2011 (Gordon 2011), several elements have been refined. These are primarily to reflect developments in
Cochrane methods, to ensure consistency across the Cochrane IBD group portfolio and ensure clinically appropriate synthesis.
• A minimum period of three months from start of therapy was sufficient to allow judgement of maintenance of remission
(previously defined as six months in the first version of the review: Gordon 2011)
• We have allowed the inclusion of no treatment control groups in this updated review with plans to analyse separately from
placebo-controlled studies.
• Sulfasazine was previously pooled with other 5-ASA agents. However, the authors discussed with the central editors of the group
and it was decided that given the specific and rationale differences in such preparations, particularly the goal of reducing side effects,
these should be treated separately. However, all other 5-ASA formulations have still been considered together for the primary analysis.
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• Gordon 2011 lists endoscopic recurrence as a primary outcome, however, we decided to report it as a secondary outcome in this
review update to ensure consistency across the Cochrane IBD group portfolio.
• We also reported adverse event data as a composite outcome not individually as proposed in Gordon 2011 to ensure consistency
across the Cochrane IBD group portfolio.
• The following secondary outcomes have been added: quality of life, radiologic relapse, serious adverse events and withdrawal due
to adverse events.
• Surgical relapse has been included as a post-hoc secondary outcome.
• For the previously published version of this review we contacted leaders in the field and 5-ASA manufacturers to identify
additional studies. We did not do this for the updated review.
• For the ’Summary of findings’ tables, we included the following outcomes: clinical relapse, endoscopic recurrence, radiologic
relapse, adverse events, serious adverse events, study withdrawal due to adverse events and health-related quality of life. We did not
pre-specify these outcomes in the published protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal [∗administration & dosage]; CrohnDisease [∗drug therapy; ∗surgery];
Mesalamine [∗administration & dosage]; Randomized Controlled Trials as Topic; Remission Induction [methods]
MeSH check words
Humans
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